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ABSTRACT 
Endothelial progenitor cells are potentially useful as a cell therapy for the treatment of ischemic 
cardiovascular diseases, but clinical outcomes have been limited likely because very few systemically 
delivered cells reach the target tissue. Biomaterials may improve outcomes of endothelial progenitor-
based therapies because they can generate well-defined microenvironments capable of directing cell 
behavior. The hypothesis guiding this thesis is that local, sustained delivery of exogenous Vascular 
Endothelial Growth Factor (VEGF) and Stromal Cell-Derived Factor (SDF) from alginate hydrogels can 
enhance recruitment of endothelial progenitors to ischemic sites and also promote their contribution to 
new blood vessel growth. 
In vitro and in vivo model systems were used to investigate the effects of VEGF and SDF on 
endothelial progenitor recruitment and regenerative potential. All studies were performed with both 
Outgrowth Endothelial Cells (OECs) and Circulating Angiogenic Cells (CACs), two populations of 
‘endothelial progenitors.’ Exposing OECs and CACs to SDF promoted adhesion to mature endothelial 
cells, and VEGF and SDF increased migration of these cells, two key steps in the homing process. 
Alginate hydrogels that release VEGF and SDF enhanced in vivo recruitment of systemically delivered 
OECs and CACs to both ischemic and non-ischemic muscle tissue. Three-dimensional in vitro assays 
modeling the initial stages of angiogenesis showed that OECs formed sprouts, while CACs did not. The 
combination of VEGF and SDF enhanced OEC sprout formation by reducing sprout initiation time and 
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improving sprout maintenance. CACs alternatively contributed to sprout formation by mature endothelial 
cells in a paracrine manner by secreting angiogenesis-promoting growth factors and cytokines, which 
were more potent than the factors secreted by OECs on a per cell basis. In vivo experiments testing the 
functional contribution of both endothelial progenitor cell types revealed that CACs, which accumulated 
in the ischemic hind-limb with local delivery of VEGF and SDF from an alginate hydrogel, promoted 
perfusion recovery better than accumulated OECs or gels alone. These studies demonstrate the therapeutic 
potential of biomaterials for enhancing endothelial progenitor cell recruitment and participation in 
neovascularization.  
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CHAPTER 1: Introduction 
 
1.1  Motivation / Problem Statement 
Cardiovascular disease is the primary cause of mortality in the developed world, leading to extensive 
research into multiple possible treatment modalities
1
. Cell therapies are increasingly attractive as 
researchers uncover the vast regenerative potential of various kinds of stem and progenitor cells
2–4
. 
Endothelial progenitor cells have been heavily investigated for their therapeutic potential in the treatment 
of ischemic cardiovascular diseases, such as peripheral vascular disease and myocardial infarction, with 
many clinical trials stemming from successful pre-clinical studies
5–8
. Unfortunately, therapeutic outcomes 
have been limited following systemic delivery of these cells, likely because too few cells reach the target 
tissue and those that do are not integrated into a tissue environment that promotes regeneration
9,10
. 
Improving the targeting capacity of systemically delivered endothelial progenitors, and enhancing their 
contribution to neovascularization are two strategies to enhance the therapeutic efficacy of these cells.  
Biomaterials can be designed to create a well-defined microenvironment in the tissue which can 
specifically direct cell behavior and regenerative potential, and may be useful for improving outcomes of 
endothelial progenitor-based therapies
11,12
. In particular, biomaterials can control the release of growth 
factors and cytokines in a spatiotemporally regulated manner to mimic endogenous signals that cells use 
for specific processes, and the concentration can be tuned to levels effective for promoting the desired 
behavior
13
. This thesis investigates the potential of using a biomaterial, designed to replicate a pro-
recruitment and pro-regenerative tissue environment, to increase endothelial progenitor targeting to 
ischemic tissue and to enhance endothelial progenitor contribution to new blood vessel formation in a 
model of peripheral vascular disease.  
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1.2  Background  
The background information presented here reviews the types of endothelial progenitors, previous work 
to utilize the cells therapeutically, and strategies, including the use of biomaterials, to enhance the 
therapeutic effect of these cells. 
Categorizing Endothelial Progenitors 
Putative endothelial progenitor cells were initially discovered in 1997 by Asahara and colleagues
14
. The 
hypothesis driving their research was that a common precursor may give rise to the hematopoietic cells 
and angioblasts that condense to form blood islands during the initial phase of vascular development
15
, 
and that it may be possible to identify an adult progenitor cell using the shared markers between the 
hematopoietic cells and angioblasts, namely CD34 and Flk-1 (or VEGFR2). CD34+ blood cells were 
magnetically sorted to a purity of 15.7%, and VEGFR2 cells were sorted to a purity of 20.0%. When 
CD34+ cells were plated on fibronectin, they adhered and proliferated for 4 weeks, whereas the CD34- 
cells did not. Plating the positive and negative populations together increased cell proliferation, cluster 
formation and also formation of tube-like structures. Further, these plated CD34+ cells took up 
acetylated-LDL and expressed higher levels of endothelial cell markers compared to freshly sorted 
CD34+ cells. Most importantly, the plated CD34+ cells were found co-localized with CD31+ cells at sites 
of new blood vessel growth in a rodent model of hindlimb ischemia. Together, these results demonstrated 
an endothelial phenotype, behavior, and apparent contribution to new blood vessel growth by the isolated 
CD34+ cells. Further, this was the first evidence of the existence of a circulating endothelial progenitor 
which could possibly participate in the growth of new vasculature. These findings motivated many 
researchers to equivalently search for and prove the existence of an endothelial progenitor cell.  
In the following years, many papers were published about these putative endothelial progenitor cells, but 
as findings varied widely, it became clear that different cell types were all being referred to as 
‘endothelial progenitors.’ There is still no single, agreed upon definition of an endothelial progenitor by 
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surface markers or gene expression, but the differing characteristics of the various cell types all 
previously called ‘endothelial progenitors’ have become more clear in recent years16–20. The different cell 
populations generally fall into three categories: 1) CD34+ cells and subsets, 2) Circulating Angiogenic 
Cells, and 3) Outgrowth Endothelial Cells. This nomenclature has been adopted here after careful review 
of the most current literature in the field. The cells in each of these categories exhibit very different roles 
in terms of how they contribute to the formation of new vasculature, and hence may differ in how they 
should be used therapeutically.  
CD34+ cells and Subsets 
Since the initially discovered EPCs were defined based on expression of CD34, many researchers began 
isolating these cells, and subsets of these cells, to gain further clarity on their role in postnatal 
vasculogenesis. In early reports, the endothelial phenotype of isolated CD34+ cells was repeatedly 
demonstrated and compared to Human Umbilical Vein Endothelial Cells (HUVECs), and in vivo CD34+ 
cells showed the ability to colonize matrigel plugs, to coat vascular grafts, and augment ischemic 
neovascularization
21–24
. CD34+ cells were also divided into various subsets, of which CD34+ VEGFR2+ 
CD133+ cells were heavily investigated. The combination that included CD133, an early hematopoietic 
marker, was thought to identify a less mature progenitor
25,26
. These cells had endothelial-like 
characteristics and lost CD133 expression as they matured
26–28
. In vivo, CD34+ VEGFR2+ CD133+ cells 
were found at sites of neovascularization and engrafted on left ventricular assist devices
24,26–29
. 
Alternatively, subjecting these cells to clonal assays revealed that CD34+ VEGFR2+ CD133+ cells also 
expressed CD45, another hematopoietic marker, and that these cells could form hematopoietic colonies, 
but not endothelial colonies
30
. Only the CD34+ CD45- population could form endothelial colonies with 
any proliferative potential
30,31
, ending the search for an endothelial progenitor within this subpopulation of 
cells. Other subpopulations of CD34+ cells have also been isolated by flow cytometry, using markers 
such as CD14 and combinations of cKit, Sca-1, and Lin, to investigate both functionality and origin
32–34
. 
While EPCs still cannot be identified by a single surface marker or any combination, it has become clear 
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that CD34+ cells represent a heterogeneous population, mostly of hematopoietic lineage. Even though 
CD34+ cells may not directly participate in blood vessel regeneration, mounting evidence does suggest 
they may act as an accessory cell in contributing to neovascularization
35
. 
Circulating Angiogenic Cells (CACs) 
Rather than using surface molecule expression to isolate endothelial progenitors, the culture protocols 
employed by Asahara and colleagues have been used to yield the Circulating Angiogenic Cell (CAC) 
population
14,17,36
. CACs are isolated from the mononuclear cell fraction of cord or adult blood by plating 
on fibronectin coated dishes in endothelial cell growth media for approximately 4 days. The adherent cells 
are termed CACs, and express endothelial surface markers, such as CD31, VEGFR2 and vWF, and these 
phenotypic similarities were used as evidence of differentiation into endothelial cells. It was quickly 
learned that CACs were not actually endothelial cells, but rather monocytes that in some ways mimic 
endothelial cell expression of surface markers when cultured in these specific conditions
37–41
. CACs 
express CD14, a marker for monocytes, maintain monocyte function in culture, and do not incorporate 
into new blood vessels
36,42–46
. But, CACs have been shown to form cord-like structures in a two-
dimensional assay for angiogenic behavior, and helped promote perfusion recovery after ischemic 
injury
42,47,48
. Interestingly, only CD14+ cells cultured to obtain CACs exhibited this blood vessel growth 
promoting behavior, whereas freshly isolated monocytes did not
47
. Other researchers have attempted to 
reduce the monocyte contribution to the CAC population by modifying the culture process. Specifically, 
the population of cells that initially adheres to fibronectin contains monocytes, which can be eliminated 
by collecting and re-plating the non-adherent population. This was first done by Ito and colleagues at 24 
hours, and later by Hill and colleagues at 48 hours
49,50
, and resulted in colony formation, with round 
centrally located cells surrounded by spindle-shaped cells at the periphery. This method has been 
commercialized into a kit containing specific media and is known as the CFU-Hill assay, in which 
reduced colony formation is used as an indicator of cardiovascular risk
50
. While quantitatively useful as a 
diagnostic, too few cells are obtained with this culture method to substantiate their use therapeutically. 
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Furthermore, the colonies do not contain a true endothelial progenitor, but instead still contain monocytes, 
and also T cells which are necessary for colony formation
36,51–54
. Even though the CAC population was 
mistakenly identified initially as an endothelial progenitor population, these cells have demonstrated their 
angiogenic promoting ability via paracrine signaling, and are thus still valuable to investigate for 
therapeutic purposes
38,46–48,55,56
. 
Outgrowth Endothelial Cells (OECs) 
The last population of ‘endothelial progenitors’ that has been widely investigated does contain cells that 
exhibit true progenitor behavior, and are called Outgrowth Endothelial Cells (OECs), or sometimes 
Endothelial Colony Forming Cells
57
. These cells were named because of their late-outgrowth behavior, 
with colonies appearing 10-14 days after isolation from cord blood or bone marrow, as opposed to the 
early outgrowth by CACs
58
. In contrast to the low or absent proliferative potential of the CAC population, 
OECs exhibited a high-proliferative potential and formed colonies in single cell re-plating assays, as 
would be expected of a true progenitor
36,57–59
. These cells were shown to originate in the bone marrow, 
but not from a CD133+ or CD45+ population, nor did they express CD14
31,58–60
. OECs demonstrated 
close similarities to endothelial cells in their surface marker expression and genetic profile, and directly 
participated in blood vessel formation
57,58,61–63
. OECs formed networks of blood vessels ex vivo through 
the process of vasculogenesis in three-dimensional matrices, and demonstrated superior survival upon 
implantation in comparison to mature endothelial cells
64–68
. Ex vivo engineered OEC vascular networks 
anastomosed with host vessels upon implantation into a mouse, and were robust enough to undergo serial 
transplantion
66,69
. OECs have also been directed to migrate out of three-dimensional scaffolds, where they 
contributed to the formation of new vessels and helped restore perfusion in a mouse model of hindlimb 
ischemia
63,70
. Together, these data demonstrate the progenitor cell properties of OECs and their 
therapeutic potential. 
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Therapeutic Use of Endothelial Progenitors 
All three types of ‘endothelial progenitors,’ CD34+ cells, CACs and OECs, have demonstrated a capacity 
to improve outcomes when used therapeutically for the treatment of ischemia in animal models. Systemic 
delivery of CD34+ cells, CACs and OECs showed increased perfusion recovery in some mouse models of 
hind-limb ischemia, and mixed transplantation of OECs and CACs appeared to have a synergistic 
benefit
34,48,59,71
. Similar trends were obtained with a biomaterial system designed to release cells locally 
into ischemic hind-limbs; CACs and OECs alone demonstrated a therapeutic benefit, while the best 
perfusion recovery was achieved with co-delivery of both cell types
63
. Further, cell delivery from within 
the biomaterial lead to enhanced recovery, as compared to local injections of either cell type, likely 
because the material protects the transplanted cells and acts as a depot from which cells can slowly 
migrate out. In addition to the use of endothelial progenitors therapeutically in models of peripheral 
vascular disease, delivery of these cells has also shown benefit in models of myocardial infaction
72–76
. The 
positive results of these studies motivated clinical investigations of the therapeutic utility of these cells. 
Endothelial progenitors have transitioned from pre-clinical animal studies into clinical trials for the 
treatment of both peripheral vascular disease and myocardial infarction (See References [6, 7, 77-79] for 
extensive review). In clinical trials, the ease with which a cell population is obtained becomes a primary 
concern, and in the case of endothelial progenitors, this has inhibited the use of CACs or OECs, as both 
cell types require days of cell culture for isolation. The most common cell sources used for clinical 
treatment of ischemia have been bone marrow mononuclear cells, Granulocyte Macrophage-Colony 
Stimulating Factor (GM-CSF)-mobilized peripheral blood mononuclear cells, and more recently CD34+ 
cells
77–79
. These cell populations likely contain some endothelial progenitors (e.g. approximately 1% of 
the total cells delivered are CD34+ cells), but are dominated by various other cell types, necessitating the 
delivery of a large number of cells (10
7
-10
9
)
7,77
. The first clinical trial in this area (TOPCARE-AMI) 
delivered bone marrow mononuclear cells into the coronary artery after myocardial infarction
80
. Results 
of this study showed improvements in left ventricular ejection fraction, regional wall motion and left 
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ventricular end systolic volume, in addition to establishing the safety and feasibility of using these cells 
therapeutically. One year and five year follow-up reports indicated that early positive results matched 
long term outcomes
81,82
. Alternatively, other clinical trials for the treatment of myocardial infarction, 
including the BOOST trial, demonstrated mixed results, where short and long term outcomes did not 
always match
83–91
.Combining the results of multiple clinical trials through meta-analysis has shown that 
bone marrow and mobilized peripheral blood mononuclear cells improved left ventricular ejection 
fraction by an average of 2.55% and 3.31%, respectively, which are small but significant differences
92,93
. 
There have been over 20 clinical trials completed using these same cell populations for the treatment of 
peripheral vascular disease
7
.  While nearly all trials had an absence of adverse events, which confirmed 
the safety of using these cells therapeutically, efficacy results were mixed. Some trials were able to 
demonstrate improvements in ankle-brachial index, leg/rest pain, and walking distance, while others did 
not show any significant differences between treated groups and placebo when cells were either delivered 
intra-arterially or intra-muscularly. Even large trials comparing bone marrow versus mobilized peripheral 
blood mononuclear cells had differing results, although these specific trials all demonstrated 
improvements in various measures with cell delivery
94–97
. Two trials explored the use of intramuscularly 
injected CD34+ cells for the treatment of critical limb ischemia. Kawamoto and colleagues showed a 
significant improvement in efficacy score, which is a combination of toe-brachial pressure index, pain 
scale, and total walking distance, and Losordo and colleagues showed a trend toward decreased 
amputation rate with an increasing number of cells delivered
78,79
. Overall, while variable results and small 
effects in clinical trials have been a challenge to interpret, outcomes have generally been positive and 
support continued investigation of these cells for therapeutic use. Progress also continues outside of the 
clinic, with a continuing search for surface markers that allow a true endothelial progenitor to be 
prospectively isolated from the circulation.  
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Potential Strategies to Improve Therapeutic Outcomes 
Improving the therapeutic effect of endothelial progenitor cells may be achieved by enhancing the 
targeting capability of delivered cells to ensure they accumulate in the tissue of interest, and increasing 
the potency of delivered cells by protecting them and promoting their contribution to new vessel 
formation. Biomaterials are of potential utility for both of these strategies, because they can be designed 
to exert exquisite control on the local tissue microenvironment, and they may allow creation of an optimal 
cell recruitment or cell delivery platform. 
First, an understanding of the molecules and cell-cell interactions that influence the ability of circulating 
endothelial progenitors to home to a tissue is necessary in order to develop therapies that can actively 
recruit these cells. The process of endothelial progenitor homing consists of mobilization from the bone 
marrow into the blood stream, followed by recruitment to the target tissue (Figure 1.1). The recruitment 
process includes responding to chemokines, adhering to the endothelium, and migrating into the local 
tissue site where the cells can then participate in blood vessel regeneration
98
. Each of these steps is 
intricately coordinated, and can potentially be targeted to enhance endothelial progenitor homing.  
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Figure 1.1 Endothelial Progenitor Cell Trafficking Processes and Key Molecules. Adapted from [100]. 
 
Role of Cytokines in Mobilization 
Endothelial progenitor cells are held in the bone marrow by gradients of Stromal Cell- Derived Factor 
(SDF), and mobilize to the blood stream when this gradient is disrupted. Systemic delivery of 
Granulocyte-Colony Stimulating Factor (G-CSF) or cyclophosphamide was shown to cause the release of 
neutrophil elastase and cathepsin G in the bone marrow, which degraded both bone marrow SDF and 
CXCR4, the receptor for SDF, and resulted in CD34+ cell mobilization from the bone marrow into the 
blood stream
99,100
. GM-CSF and Vascular Endothelial Growth Factor (VEGF) were also shown to 
stimulate mobilization of endothelial progenitors, which was further enhanced with co-delivery of a 
CXCR4-antagonist
101–103
. Alternatively, instead of disrupting the bone marrow SDF levels, increasing the 
concentration of SDF in the blood and effectively reversing the direction of the SDF gradient caused 
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progenitor mobilization
104
. Delivery of thrombopoietin and soluble kit ligand also increased the plasma 
SDF concentration by stimulating release from platelets
105
. Lastly, induction of ischemia in a mouse hind-
limb model resulted in elevated plasma SDF concentration and subsequent mobilization of 
progenitors
102,105,106
. These in vivo data illustrate the strong chemoattractive effect of SDF on progenitors, 
in addition to repeated demonstrations of this effect in transwell assays
99,100,107–109
.  
Role of Cytokines in Recruitment 
Once endothelial progenitors are in the circulation, they must then be recruited to a target tissue in order 
to exert a therapeutic effect. Not only does SDF regulate progenitor cell mobilization, but it was shown to 
be expressed in ischemic tissue and exerted a chemoattractive effect on circulating progenitors, helping to 
recruit these cells to the tissue
106
. Ischemia also caused local upregulation of IL-8 and Gro-α, two 
cytokines that demonstrated a chemoattractive effect on CD34+ cells
110
. VEGF was similarly shown to 
induce recruitment of progenitor cells
111,112
. Exposure to chemoattractants is followed by adhesion of the 
circulating progenitors to the endothelium and extravasation from the blood vessel into the tissue of 
interest. Similar to circulating lymphocytes, endothelial progenitors use integrin – adhesion molecule 
interactions for adhesion and migration. CD34+ cells were shown to use both α4β1 and αLβ2 integrins for 
adhesion, but transendothelial migration was only dependent on αLβ2, which was followed by α5β1-
dependent migration on the extracellular matrix protein, fibronectin
113,114
. SDF exposure enhanced CD34+ 
cell adhesion, likely by a similar mechanism to that used by lymphocytes
107,113–116
. These studies together 
demonstrated that SDF exposure and concentration gradients significantly impact multiple processes 
involved in endothelial progenitor cell trafficking, which subsequently encouraged investigation of the 
possible uses of SDF for enhancing the homing of circulating cells to tissues of interest.  
Multiple modes of exposure to SDF have been investigated for their utility in controlling endothelial 
progenitor homing, including simple methods such as pre-treatment of cells or local tissue injections, as 
well as cell transfection procedures and the use controlled-release biomaterials for more prolonged 
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exposure. CD34+ cells that have be pre-stimulated with SDF before systemic injection increased capillary 
density in a mouse model of hind-limb ischemia, and similarly, an intramuscular injection of SDF in 
ischemic hind-limbs increased recruitment of systemically delivered cells
108,114
. Since the effects of SDF 
are limited in these cases due to short exposure time, researchers alternatively injected cells that were 
transfected to express SDF in order to increase the concentration locally and further affect endogenous 
cell recruitment. Both mesenchymal stem cells and skeletal myoblasts transfected to express SDF and 
delivered into the ischemic myocardium reduced infarct size, increased blood vessel density and 
improved overall left ventricular contractile function
117,118
. Genetic modification of cells may upregulate 
cytokine expression and secretion in a well-defined in vitro environment, but once implanted in vivo, the 
effective concentration of SDF secreted by the cells is left uncontrolled. 
Potential Roles for Biomaterials 
Biomaterials can be designed to spatiotemporally control the release of cytokines and growth factors that 
direct cell behavior in a local tissue area and/or effect cell trafficking at a distance, and could be used to 
increase the targeting capability of systemically delivered endothelial progenitors
11
. For example, delivery 
of VEGF followed by slower release of PDGF from a poly-lactide-co-glycolide scaffold enhanced local 
blood vessel regeneration and maturation in a mouse model of hind-limb ischemia
119
. Similarly, co-
delivery of VEGF and an anti-VEGF antibody in a layered scaffold created a spatially regulated 
angiogenic zone, where blood vessel growth was locally promoted
120
. SDF has also been delivered from 
various materials for local and circulating cell recruitment purposes. Heparinized-collagen and 
poly(lactide-co-glycolide) scaffolds that were loaded with SDF promoted hematopoietic cell 
infiltration
121,122
. SDF-releasing polycaprolactone and poly(lactide ethylene oxide fumarate) scaffolds 
recruited mesenchymal stem cells and bone marrow stromal cells, respectively
123,124
. Subcutaneous 
implantation of an SDF-releasing poly(ethylene glycol)-heparin hydrogel was shown to recruit 
systemically delivered CACs, and SDF-releasing gelatin hydrogels lead to enhanced angiogenesis within 
the gel
125,126
. These studies demonstrate the robust cell recruitment capabilities of SDF-releasing 
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biomaterials, likely due to the steep concentration gradient created between the scaffolds and surrounding 
tissue. Since endothelial progenitors are strongly attracted to gradients of SDF, as previously discussed, 
biomaterials could be designed to increase homing of systemically delivered cells to the scaffold 
implantation site. 
Biomaterials can also potentially increase the potency of delivered endothelial progenitors by protecting 
them and promoting their contribution to new blood vessel formation. For endothelial progenitors to 
effectively contribute to new vasculature following localization to ischemic tissue, it is likely they must 
be in an environment where the surrounding cells are working together to support vessel growth. VEGF is 
one of the strongest promoters of angiogenesis, and is essential for the formation of new blood vessels 
and recovery from ischemia
127,128
. VEGF is also necessary for survival of cultured endothelial progenitors, 
and promotes proliferation of OECs. OECs that were delivered to ischemic tissue in scaffolds containing 
VEGF demonstrated increased blood vessel density compared to OECs delivered without VEGF
63
. Here, 
the VEGF likely was acting both on the OECs and on the endogenous endothelial cells, as well as other 
cells participating in regeneration, since delivery of VEGF alone from polymer scaffolds enhances 
neovascularization in mouse models of hind-limb ischemia
129–131
. Still, the OECs alone could not 
compensate for the lack of VEGF, likely because prolonged exposure to VEGF is crucial for the creation 
of a pro-angiogenic environment
63
. Hence, establishing this angiogenic environment using biomaterials to 
deliver VEGF, or possibly other factors, may be required to enhance endothelial progenitor participation 
in neovascularization.  
Even with establishment of a pro-angiogenic environment, it is still possible that too few cells are 
recruited to ischemic tissue to effectively enhance regeneration, in which case biomaterials can be used to 
deliver endothelial progenitors, in addition to growth factors. Delivery of OECs and CACs within an 
alginate hydrogel that was designed to deploy the cells into the surrounding tissue resulted in superior 
perfusion recovery compared to delivery of either cell type alone within the hydrogel or local injection of 
both cell types into the tissue without the protective alginate hydrogel
63
. Lastly, rather than encourage 
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participation of endothelial progenitors with controlled recruitment or delivery from biomaterials, the 
vasculature could be grown ex vivo on a biomaterial and then implanted. OECs have been pre-formed into 
networks of blood vessels within three-dimensional scaffolds, and anastomosed with host vasculature 
upon implantation
66–69
. Extensive research has been performed on the growth and engineering of these 
vascular networks, most often to support specific tissue engineering applications, but their use could 
easily be adapted for therapeutic delivery of endothelial progenitors for the treatment of ischemic 
diseases
132–134
. 
Summary 
In summary, endothelial progenitors have demonstrated significant therapeutic potential since their 
discovery, despite years of confusion over the types of ‘progenitors’ and the lack of a surface marker-
defined true progenitor cell. CD34+ cells, CACs and OECs each exhibit unique properties that encourage 
continued investigation of their individual roles in contributing to neovascularization, and exploration of 
the best delivery methods for each cell type. Mononuclear cell fractions containing CD34+ cells have 
been used in clinical trials for the treatment of peripheral vascular disease and myocardial infarction, but 
with limited success. Enhancing the targeting capability of systemically delivered cells should improve 
therapeutic outcomes by increasing the number of cells that reach the diseased tissue and subsequently 
participate in regeneration. Finally, the use of biomaterials to improve cell recruitment and tissue 
regeneration is promising, because they can be designed to control the release of cytokines and growth 
factors that influence endothelial progenitor homing and survival, such as SDF and VEGF.  
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1.3  Hypothesis and Specific Aims 
 
The hypothesis guiding this research is that local, sustained delivery of exogenous VEGF and SDF 
from alginate hydrogels can enhance recruitment of endothelial progenitors to ischemic sites and 
also promote progenitor cell contribution to new blood vessel growth. 
 
Aim 1: Evaluate effects of VEGF and SDF in vitro on the adhesion and migration of OECs and CACs, 
and determine if this combination of factors increases in vivo recruitment of OECs and CACs to ischemic 
tissue. 
Aim 2: Use in vitro sprouting assays to model the potential contributions to new blood vessel formation 
by OECs and CACs recruited to ischemic hind-limbs by VEGF and SDF-releasing scaffolds, and 
determine the functional ability to restore perfusion in vivo. 
 
1.4  General Strategy and Thesis Outline 
To investigate the guiding hypothesis for this thesis, two aims were developed to focus on 1) endothelial 
progenitor cell recruitment and 2) contribution to new blood vessel formation. Within each of these aims, 
the effects of VEGF and SDF were investigated in order to determine if exposure to these factors can 
increase recruitment and enhance regeneration in a therapeutically effective manner. An injectable 
alginate hydrogel system previously developed in the lab was used to provide the local, sustained release 
of VEGF and SDF during in vivo experiments
131
. Further, as discussed in the background section, there 
are three types of ‘endothelial progenitors.’  Previous studies have explored the recruitment potential of 
CD34+ cells, as the use of this cell type has already transitioned into the clinic
79,108,114
. Few, if any, 
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publications have examined methods to improve recruitment and therapeutic efficacy of systemically 
delivered OECs or CACs. In this thesis, the therapeutic utility OECs and CACs was examined and 
compared. 
Chapter 2 is dedicated to investigating Aim 1, using both in vitro and in vivo model systems. Specifically, 
the mechanisms that OECs and CACs use for adhesion were compared to the well-understood integrin – 
adhesion molecule interactions used by lymphocytes, and the effect of SDF on endothelial progenitor 
adhesion was uncovered. VEGF was not expected to affect adhesion, and was not tested in these studies. 
The effect of VEGF and SDF on OEC and CAC migration was tested in transwell assays. In vivo, VEGF 
and SDF-releasing alginate hydrogels were tested for their ability to increase recruitment of both OECs 
and CACs to ischemic and non-ischemic tissue. 
Chapter 3 is focused on Aim 2, modeling and uncovering the contributions to blood vessel formation by 
OECs and CACs, both in vitro and in vivo. Three-dimensional sprouting assays were used to model direct 
participation in blood vessel formation and also indirect contribution in a paracrine manner. The effect of 
VEGF and SDF on each of these processes was examined. Last, OECs and CACs, which were 
systemically delivered and subsequently recruited to ischemic hind-limbs by VEGF and SDF-releasing 
alginate hydrogels, were tested for their ability to restore functional perfusion in vivo. 
Chapter 4 discusses the major conclusions, implications and future directions of this work. The 
appendices address additional projects related to this work, which did not otherwise fit into this thesis or 
require further investigation or analysis. Supplemental figures for Chapters 2 and 3 are included in the 
appendices, as well as detailed protocols. 
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1.5  Significance 
The use of various types of stem and progenitor cells as therapies is continuously expanding as the 
regenerative potential of these cells is uncovered. Often though, the results of pre-clinical studies and 
clinical trials using cell therapies are mixed, and demonstrate only small effects. These poor outcomes are 
most likely due to too few cells reaching the target tissue, and those that do are not being incorporated 
into an environment that allows their contribution to regeneration. Enhancing the targeting of systemically 
delivered cells and creating microenvironments that promote recovery are two strategies to improve the 
therapeutic efficacy and outcomes. This thesis investigates the potential of a biomaterial system to 
improve endothelial progenitor cell accumulation and participation in blood vessel regeneration in vivo in 
ischemic tissue, by releasing factors that are shown to increase adhesion, migration and sprout formation 
in in vitro assays. The use of biomaterials for cell recruitment purposes is basically non-existent in the 
clinic, and therefore every demonstration of efficacy with these systems may impact their clinical 
development and future use. Even incremental improvements in cell targeting may have significant 
effects on the overall outcome. 
Scientifically, researchers who study ‘endothelial progenitors’ have largely focused on defining the cell 
type and discovering the correct identification markers. While this is reasonable considering the age of the 
field and the early discrepancies discussed previously, the studies presented here demonstrate the specific 
roles of OECs and CACs in contributing to neovascularization. These results confirm that only OECs can 
directly participate in blood vessel growth by forming new sprouts. The potential to contribute in a 
paracrine manner is investigated, and a panel of angiogenic factors secreted by each cell type is presented. 
Further, as all of these studies are completed with both OECs and CACs in direct comparison, the 
therapeutic potential of each cell type is elucidated, offering useful information as to how each cell type 
may possibly be used in the clinic. 
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CHAPTER 2: 
Effects of VEGF and SDF on Recruitment of 
Endothelial Progenitor Cells 
 
2.1  Purpose of Chapter 
This chapter addresses the hypothesis that local, sustained delivery of Vascular Endothelial Growth 
Factor (VEGF) and Stromal Cell-Derived Factor (SDF) can improve endothelial progenitor recruitment to 
ischemic hind-limb muscle in mice by increasing their adhesion and migration, two key steps in the 
homing process. In vitro assays were used to determine the influence of SDF on the adhesion of 
Outgrowth Endothelial Cells (OECs) and Circulating Angiogenic Cells (CACs) to endothelial cells in 
both static and shear-controlled environments. VEGF was not expected to play a role in cell adhesion, and 
therefore was not tested in these assays. The role of both VEGF and SDF on progenitor cell migration 
was also determined. In vivo, alginate gels that steadily release VEGF and SDF were tested for the ability 
to enhance recruitment of OECs and CACs to ischemic and non-ischemic muscle tissue. This chapter fits 
into the overall hypothesis of this thesis by determining whether VEGF and SDF can enhance the 
recruitment efficiency of systemically delivered endothelial progenitors. 
 
2.2  Introduction 
Cardiovascular disease is the primary cause of mortality in the developed world, a significant portion of 
which is caused by ischemic diseases, including peripheral vascular disease
1,2
. Peripheral vascular disease 
is characterized by blockages in arteries of the limbs, which reduces blood flow and results in ischemic, 
unhealthy tissue downstream
3
. Endothelial progenitor cells can contribute to the growth of new blood 
vessels, potentially restoring the health of the tissue
4–6
. There are currently over 200 clinical trials 
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involving endothelial progenitors for the treatment of various forms of cardiovascular disease, including 
ischemic diseases
6–8
. Many of these clinical trials use systemic infusion of cells into the blood stream as 
the delivery method. Systemic infusion of progenitor cells is generally attractive because of the simple 
delivery procedure, but this approach often shows poor efficacy due to high cell death and lack of control 
over cell targeting. Despite increasing clinical investigation, there is still a need to improve the limited 
therapeutic efficacy associated with systemic delivery of endothelial progenitor cells.  
One possibility for improving therapeutic outcomes is to actively recruit systemically delivered cells to 
the tissue of interest, thereby improving the targeting efficiency of cell delivery.
9
 As many steps are 
involved in the process of cell recruitment, there is potential to influence the ability of cells to home to 
target tissues at multiple stages. First, a circulating cell must adhere to the inner surface of a blood vessel 
at a specific location
9–11
. This is followed by migration to a position where the cell can participate in 
regeneration, often outside of the blood vessel
9–11
. There are many signaling molecules that regulate each 
of these steps mentioned here, the combination of which help to form a specific microenvironment that 
encourages cell recruitment
11-12
. Artificially replicating or enhancing this pro-recruitment 
microenvironment could enhance cell targeting to that location. For these studies, SDF and VEGF were 
chosen for delivery because they both play significant roles in regulating endothelial progenitor cell 
trafficking. SDF is highly involved in the recruitment and retention of endothelial progenitors in the bone 
marrow, and also acts as a chemotactic factor for multiple cell types, with the ability to influence 
adhesion and migration. Specifically, disruption of SDF gradients in the bone marrow leads to 
mobilization of progenitors into the circulation, where the progenitors can then be recruited to specific 
tissues
13–17
.  Exposure to SDF can also promote in vitro CD34+ cell adhesion to endothelial cells in flow 
chambers, and migration through transwells
18–21
. Local injection of SDF into muscle tissue has been 
shown to influence the in vivo recruitment of endothelial progenitors in a mouse model of ischemia
22
. 
VEGF, in addition to potently promoting angiogenesis, also plays a role in mobilization of progenitors 
from the bone marrow, and is a well-known chemoattractant for endothelial cells
23
. Further, endothelial 
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progenitors can migrate according to gradients of VEGF delivered from alginate hydrogels
24
. Taken 
together, VEGF and SDF have both been shown to regulate key steps in progenitor cell trafficking, and 
for this reason were selected and tested for their ability to enhance targeting. 
The use of polymeric biomaterials is potentially advantageous for these studies because they can be 
designed to release signaling molecules in a spatiotemporally controlled manner in order to create specific 
microenvironments that can regulate cell behavior
25
. The controlled release of these molecules (e.g. 
growth factors and cytokines), as opposed to a bolus injection, protects them from rapid enzymatic 
degradation, resulting in sustained presentation over a longer therapeutic window. Our lab has extensive 
experience creating biomaterials that promote angiogenesis for the treatment of ischemia
26–35
. For 
example, poly lactide-co-glycolide (PLG) scaffolds that first release VEGF, followed by a slower release 
of Platelet-Derived Growth Factor, were designed to not only promote the formation of new blood 
vessels, but also to support the maturation of these vessels
28,30
. PLG scaffolds can also be layered to 
spatially separate VEGF release from release of an anti-VEGF antibody, which creates a temporally 
stable and spatially restricted zone of angiogenesis
36
. Alternatively, alginate hydrogels can be designed to 
release VEGF with a decreasing rate over time, which was the profile determined to promote the most 
endothelial cell sprouting in a 3D model of angiogenesis
32
. Here, I used an injectable alginate hydrogel to 
control the release of VEGF and SDF.  
Lastly, all experiments were performed with both OEC and CAC populations. OECs and CACs are both 
potentially relevant as therapies for ischemic diseases, but the contributions to new blood vessel growth 
from each cell type differ
37–39
. OECs exhibit a high proliferative potential, allowing for significant 
expansion in culture and therefore a near-unlimited therapeutic cell source
38,40
. OECs can also directly 
participate in blood vessel formation
24,41,42
. CACs alternatively are very limited in number and do not 
form blood vessels, but secrete potent angiogenic factors, and hence potentially contribute to new vessel 
formation in a paracrine manner
43–45
. The direct comparison between OECs and CACs in these studies 
may therefore guide future decisions on how each of these cells types should be used therapeutically. 
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2.3  Materials and Methods 
Cell Isolation and Characterization 
Human cord blood was used for OEC/CAC isolation within 12 hours from collection. Cord blood was 
diluted 1:1 with Hanks Balanced Salt Solution (HBSS) and gently placed on top of Histopaque 1077 
(Sigma #10771-500ml). Samples were centrifuged at 740g (OECs) and 400g (CACs) for 30 minutes with 
no brake. Mononuclear cells were then collected and washed with HBSS. Remaining red blood cells were 
lysed and cells were washed twice with HBSS. For OEC isolation, cells were resuspended in EGM-2MV 
(Lonza #CC-3202) supplemented with 10% FBS and plated on Collagen coated dishes (BD #354400). 
Media was changed after two days, and every day until colonies appeared (day 10-14). Colonies were 
replated and maintained in EGM-2MV media while in use; OECs were used between passages 2 and 6. 
For CAC isolation, cells were plated on fibronectin-coated dishes (BD #356008) in EGM-2MV without 
hydrocortisone and supplemented with 10% FBS. Additional media was added to the cells on day 4, and 
attached cells at day 7 were immediately used for experiments. 
Human B-lymphocytes were obtained from Coriell Cell Repository (#GM20431) and were cultured in 
RPMI 1640 with 2mM L-glutamine and 15% FBS. Culture of cord blood cells was exempt from 
Institutional Review Board approval, and lymphocyte cell culture was approved by the Institutional 
Review Board at Harvard University. 
OEC and CAC surface marker expression was characterized via flow cytometry. Antibodies to the 
following markers were used for detection: CD31 (BD Pharmingen #555445 ), CD45/CD14 (BD 
#340040 ), VEGFR2 (R&DSystems # FAB357P), CXCR4 (R&DSystems #FAB170P ), CD34 (BD 
Pharmingen #555821), ICAM (BDPharmingen #559047), VCAM (BDBiosciences #555645), and β2 
integrin (CalBiochem #217660 ). ICAM, VCAM and β2 integrin required the application of a secondary 
antibody for fluorescent detection (Invitrogen #A11029). Flow cytometry data was collected on a BD 
LSRFortessa (Franklin Lakes, New Jersey) and analyzed with FlowJo software (Tree Star, Inc. Ashland, 
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OR). Relative OEC and CAC integrin expression was characterized using an antibody-based adhesion 
array according to the manufacturers protocol (Millipore #ECM535). Briefly, single cell suspensions of 
OECs or CACs were plated into the wells provided, which were coated with an antibody for each assayed 
integrin. After 1hour, un-attached cells were gently rinsed. OECs or CACs which had been captured by 
the integrin antibody were then lysed and stained with the provided CyQuantGR® dye, and fluorescence 
was measured on a plate reader (Bio-Tek Synergy H1 Plate Reader, Winooski, VT) at excitation 485nm 
and emission 528nm.  
Luciferase OEC Transduction 
Reporter gene constructs Luciferase plasmid pGreenFire1-CMV (cat# TR011PA-1) and packing 
plasmid pPACKH1-XL HIV (cat# LV510A-1) were purchased from System Bioscience. To produce the 
second-generation replication-incompetent lentivirus, 1.5 million 293TN cells (Cat. # LV900A-1) were 
seeded onto 10 cm petri-dishes in 10 ml DMEM (10%FBS, 1x glutamine, 1x PenStrep) per dish and 
incubated for 24 hours at 5% CO2, 37°C until 50-70% confluency. On day 2, media was changed to 
DMEM (10% FBS, 1x glutamine, without PenStrep). To create a plasmid mix, 400µl DMEM (without 
FCS, glutamine and PenStrep), 6µl of Luciferase plasmid (2µg/dish), and 20µl pPACK Packaging 
Plasmid Mix (10µg/dish) was added to a polystyrene tube and mixed gently. In a second tube, 400µl 
DMEM (without FCS, glutamine and PenStrep) and 30µl Lipofectamine 2000 (cat# 11668-027) were 
mixed gently. These two solutions were combined and incubated at room temperature for 15 minutes. The 
mixture was added drop-wise to the 293TN cells in a petri-dish, gently mixed by tilting, and then allowed 
to incubate for 48 hours at 5% CO2, 37°C. The viral supernatant was collected 48 hours after transfection 
and passed through a 0.2µm filter prior to aliquoting and storing in polystyrene tubes at -80°C. 
5ml of thawed viral supernatant, 15µl of protamine sulfate (concentration 4µg/µl, Life cell technologies, 
cat# A11559IK), and 5ml EBM-2 + 10%FBS was added to 70% confluent OECs in a T75 flask and 
incubated at 5% CO2, 37°C. After 48 hours, the cells were washed twice with PBS, and media was 
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changed to EGM-2MV (without antibiotics or hydrocortisone). Luciferase expression was verified with a 
plate reader (Bio-Tek Synergy H1 Plate Reader, Winooski, VT) using Bright-Glo™ Luciferase Assay 
System (Promega, Cat# E2610) following manufactures instructions.  
Adhesion Assay 
HMVECs (Lonza #CC-2543) or HUVECs (Lonza # C2517A) were grown to confluence on 12mm 
diameter, Human Collagen IV (BD #354245) coated glass cover slips in 24 well plates with EGM-2MV 
(Lonza #CC-3202) or EGM-2 (Lonza # CC-3162) media, respectively (n=6 for each condition assayed in 
each experiment). For some conditions, media in contact with endothelial cells was supplemented with 
50ng/ml TNFα (Peprotech #300-01A) for 8 hours before beginning experiments. OECs/CACs were 
fluorescently labeled with octadecyl-rhodamine (Life Technologies # O-246) for visualization, and 
trypsinized and prepared to a single cell suspension in EBM-2 + 5%FBS. OECs/CACs were then gently 
applied on top of HMVECs or HUVECs. SDF (R&D #350-NS) presentation on the surface of endothelial 
cells was achieved by incubating HMVECs or HUVECs with 500ng/ml SDF for 1 hour prior to starting 
experiments. The SDF in solution was then rinsed with fresh media, and all wells were changed to EBM-
2 + 5%FBS at the start of the experiment. For conditions with SDF present during adhesion, 100ng/ml 
SDF was added to the HMVECs or HUVECs immediately before application of the OECs/CACs. A β2 
antibody
46,47
 (CalBiochem #217660 ) was also used to block adhesion of OECs/CACs, and was given to 
these cells for 5 minutes prior to their application on top of HMVEC or HUVEC monolayers. OECs and 
CACs were allowed to adhere for 30 or 60 minutes. At the end of this time, cover slips were removed 
from the well, gently rinsed in PBS, and then fixed in 20% methanol in PBS for 5 minutes. Cover slips 
were then mounted on glass slides with ProLong gold Anti-fade Reagent with Dapi (Life Technologies 
#P36935), and kept at room temperature in the dark for 24 hours and at 4
o
C thereafter. Cell adhesion was 
quantified by imaging each 12mm slide 6 times, and the mean number of cells per image for each slide 
was used to determine the mean and standard deviation for each condition (Zeiss Axio Observer Z1, 
Thornwood, NY; Image J software). Each experiment was repeated 2-6 times. 
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ICAM Adhesion Assay 
Non-tissue culture treated plates were placed in a plasma generator (SPI Plasma-Prep II Plasma Etcher, 
West Chester, PA) for 45 seconds to render the surface hydrophilic for ICAM protein (eBioscience # 
BMS313) adsorption. 5mg/ml recombinant human soluble ICAM was diluted in PBS and quickly applied 
to the well plate surface following plasma exposure; alternatively 1% BSA in PBS was applied to the 
wells as a negative control. Plates were then placed at 4
o
C overnight to allow protein adsorption. Prior to 
starting the experiment, protein was aspirated from each well and blocking buffer (PBS with 1% BSA) 
was applied for 1 hour at room temperature to block the plate surface where ICAM had not adsorbed. 
Blocking buffer was aspirated and 300ul of adhesion buffer (HBSS with 0.1% BSA and 25mM HEPES) 
was applied to each well. Other conditions include the addition of SDF and 100ng/ml in adhesion buffer, 
2mM MnCl2 in adhesion buffer, or 5mM EDTA diluted in PBS without Calcium and Magnesium. 
OECs/CACs were trypsinized and resuspended in adhesion buffer. For conditions using blocking β2 
integrins, 0.5ug of β 2 blocking antibody was applied to the OEC/CAC cell suspension 5 minutes before 
placing cells in the well plate. OECs/CACs were allowed to adhere for 30-60 minutes at 37
o
C and 5% 
CO2. Wells were then gently washed with PBS three times to remove non-adherent cells. 100ul of 
TrypLE Select without phenol red (Life Technologies #12563029) was added to each well and placed in 
the incubator for 5 minutes to detach adherent cells. 50ul of adhesion buffer was then added to each well, 
along with 50ul of lysis buffer (3mM Na2HPO4, 0.8mM NaH2PO4, 0.1M NaCl, 0.25%v/v Triton-100) 
with 1ul of CyQuant GR dye(Life Technologies #C7026). The plate was allowed to sit at room 
temperature for 15 minutes protected from light. Lysed OEC/CAC cell suspensions in each well were 
then mixed thoroughly and pipetted into a 96 well black plate. Fluorescence was read at excitation 485nm 
and emission 528nm for quantification (Bio-Tek Synergy H1 Plate Reader, Winooski, VT). 
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Flow Adhesion Assay 
COMSOL MultiPhysics 4.2 software (COMSOL, Inc. Burlington, MA) was used to verify laminar flow 
properties of chosen dimensions for PDMS-based parallel flow channels. A model was created using 
Laminar Flow and Transport of Dilute Species physics settings, and the chosen channel geometry and 
flow parameters were input into the model. The model was solved, and shear forces and flow velocities 
were calculated. Stamps for PDMS flow chambers were cut out of 80µm thick MACtac (#8389-00-2411) 
to the dimensions verified by the COMSOL model using a cutting plotter (Graphtec #CE5000-60). 
Stamps were 1cm wide and 2cm long with triangular caps at the ends, and were placed on silica wafers to 
create a mold. PDMS (Sylgard® 184, Dow Corning #3097358-1004) was poured over the mold, 
degassed, and cured overnight at 65
o
C. The PDMS channels were irreversibly bonded to a glass slide after 
plasma treatment. HMVECs were then cultured to confluence on the collagen-coated glass surface with 
EGM-2MV media flowed over the surface at 0.1dyne/cm
2
. One million CFSE-stained (eBioscience # 65-
0850-84) OECs or CACs were then flowed over the surface for 20 minutes in EBM-2 + 5% FBS. SDF 
was presented on the surface of HMVECs by flowing 500ng/ml SDF over the surface for 1 hour prior to 
beginning the experiment. Free SDF in the device was rinsed prior to adding OECs or CACs. 
Alternatively, SDF was presented in solution by adding 100ng/ml SDF to the suspension of OECs or 
CACs as they flowed over the HMVEC surface. Flow continued for 20 minutes after cell administration 
to rinse any unattached cells. Dapi was then added to the devices and cells were fixed with 0.5% 
paraformaldehyde. 30-60 images, in areas where HMVEC confluence was confirmed, were captured for 
each device to quantify cell adhesion. Each experiment was repeated three times. 
Transwell Migration 
Transwell membranes with 8µm pores (Corning # 3422) were used to assess OEC migration, while 
membranes with 5µm pores (Corning #3421) were used for CAC migration. Transwell membranes were 
coated with 5µg/ml Collagen IV in 10mM acetic acid overnight at 4
o
C, and were then rinsed thoroughly 
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with PBS. EBM-2 media with 5% FBS was supplemented with 50ng/ml VEGF (R&D Systems #293-
VE), 100ng/ml SDF or the combination (n=6-10 individual membranes), and this was applied to the 
bottom of the wells. Single cell suspensions of either OECs or CACs were prepared and 50,000 cells were 
applied to the top of 6mm diameter membranes. Plates were then allowed to incubate at 37
o
C and 5% CO2 
for 4 hours. For OECs, cells remaining on the top of membranes were removed by wiping with a cotton 
swab, leaving migrated cells on the bottom of the membrane for quantification. Membranes were then 
removed from the transwell, mounted on glass slides with ProLong Gold Anti-Fade with Dapi and 
covered with a glass coverslip. Slides were protected from light and allowed to sit at room temperature for 
24 hours before being stored at 4
o
C until imaging. To quantify migration, 7 fields of view per membrane 
were imaged under dapi fluorescence. For CACs, cells that migrated through the membrane to the bottom 
of the transwell were counted. 
Alginate Gel Preparation 
Gels were prepared as previously described
32,48
.  In brief, Ultra-pure MVG alginate was obtained from 
Pronova (# 4200106). MVG alginate was irradiated at 3MRad to obtain low molecular weight polymer 
chains. 1% of carboxylic acid groups on both high and low molecular weight alginates were oxidized to 
aldehyde groups with sodium periodate, to produce a hydrolytically labile polymer backbone
49
. The 
reaction was stopped with the addition of ethylene glycol after 17 hours. Alginate polymers were then 
dialyzed in 3000MWCO membranes for 3 days with repeated water exchange, frozen and lyophilized for 
storage. One day prior to use, both HMW and LMW alginate were reconstituted with EBM-2 to 2%w/v. 
VEGF and SDF were then added to a mixture of 75% LMW and 25% HMW alginates. 40µl of 0.21g/ml 
CaSO4 was added per 1ml of alginate to crosslink the gel and was mixed between two 1ml syringes 
connected with a Leur-Lok union. Gels were allowed to crosslink for at least 30 minutes prior to use. 
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Cytokine Release from Alginate Gel 
5µCi of 
125
I-radiolabeled VEGF was purchased from Perkin Elmer (#NEX328025UC), and SDF (R&D 
Systems #350-NS) was custom labeled with 
125
I by Lofstrand Labs Ltd (Gaithersburg, MD). Alginate gels 
were prepared as described above, with 3ug of unlabeled-VEGF or 2ug of unlabeled-SDF and 
approximately 0.05µCi of either 
125
I-VEGF or SDF added per 50ul of alginate prior to cross-linking with 
CaSO4. Immediately after the addition of CaSO4, a 25G needle was connected to the 1ml syringe 
containing the alginate, and 50ul volume gels were distributed into polypropylene tubes. Gels were 
allowed to crosslink in the tubes for 1 hour before 2 ml of PBS containing Ca
2+
 and Mg
+
 with 1% BSA 
was gently added to each tube. CPM of the radiolabeled protein released into the supernatant and 
remaining in the gel were measured at multiple time points with a gamma counter (1470 WIZARD, 
PerkinElmer, Waltham, MA). 
Hind-limb Ischemia Mouse Model and Muscle Tissue Processing 
All animal experiments were performed in accordance with IACUC approved protocols. Hind-limb 
ischemia surgery was performed on C57BL6/J mice (#000664, Jackson Laboratory, Bar Harbor, ME) less 
than 10 weeks old, as previously described
31,48
.  Briefly, mice were given an intraperitoneal injection of a 
Ketamine/Xylazine cocktail to induce anesthesia. An incision was then made at the inner thigh, exposing 
the underlying muscle and the external iliac artery and vein, and the hypogastric artery and vein. Two 
ligatures were placed around the external iliac artery and vein and one was placed around the femoral 
artery and vein. The external iliac vessel was cut between the two suture knots. Alginate gels containing 
2ug of SDF and 3ug of VEGF or control gels (no factors) were then injected intramuscularly under the 
ligation site. The incision was closed with 7mm staples. One day after surgery, OECs or CACs in culture 
were stained for 10 minutes with 3ul of Vybrant™ DiD dye per million cells (Molecular Probes #V-
22887), and were delivered to the mouse blood stream using an intracardiac injection to prevent first pass 
accumulation in the lungs. At 48 hours, the semimembranosus, semitendinosus, gracilis and adductor 
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muscles surrounding the vessel ligation site on the ischemic limb and the same muscles from the 
contralateral, non-ischemic limb were collected and enzymatically digested with 250 U/ml Collagenase II 
(Life Technologies #17101-015) in DMEM for 2 hours at 37
o
C with agitation followed by trituration with 
glass pasteur pipette. Samples were then subjected to a second digestion step with 50U/ml Collagenase II 
and 1U/ml dispase II (Roche #04942078001) in DMEM at 37
o
C for 2 hours with agitation, and were 
vortexed at high speed for 1 minute before being passed through 40µm filters in preparation for flow 
cytometry analysis. Alternatively, gastrocnemius muscles isolated from ischemic and contralateral, non-
ischemic hind-limbs were processed for frozen tissue sectioning. Muscles were cryoprotected in 30% 
sucrose in PBS at 4
o
C overnight, and then in 50% OCT compound (Tissue-Tek #27050) + 15% sucrose in 
PBS at 4
o
C overnight, before being embedded and frozen in OCT compound. Samples were cut 
perpendicular to muscle fibers, midway through the gastrocnemius muscle into 10µm thick sections and 
placed on glass slides. Cryosections were rehydrated in 70% ethanol, and PBS. Rehydrated sections were 
permeabilized in blocking buffer (1% BSA fraction V (Sigma #85040) + 10% normal goat serum 
(Jackson ImmunoResearch Laboratories #005-000-001) in PBS, containing 0.2% TritonX-100 (Sigma-
Aldrich #X100)). A primary mouse anti-human CD31 antibody (BD #555444) was applied to detect 
OECs, followed by a goat anti-mouse Alexafluor647-conjugated secondary antibody (Life Technologies 
#A21235), used for visualization under fluorescence. Cell nuclei were stained during cover slip mounting 
with ProLong Gold Anti-fade with Dapi (Invitrogen #P36935). Muscles were imaged at 4x and 20x 
magnification with a Nikon Eclipse E800 microscope (Nikon Instruments Inc., Melville, NY) equipped 
with an Olympus DP70 camera.  
Additionally, Luciferase-transduced OECs were systemically delivered via intracardic injection one day 
after ischemia surgery to assay for localization to the ischemic hind-limb. At 48 hours following surgery, 
RediJect D-Luciferin Ultra Bioluminescent Substrate (Perkin Elmer #760505) was delivered into the 
intra-peritoneal cavity (150mg Luciferin / kg body weight) 10 minutes prior to animal sacrifice. Mouse 
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hind-limbs were detached and skin was removed prior to imaging with an InVivo Imaging System (IVIS 
Spectrum, Perkin Elmer, Waltham, MA). 
Flow Cytometry of Cells Isolated from Hind-limb Muscle 
Single cell suspensions of digested muscle were analyzed via flow cytometry for the presence of DiD-
labeled OECs or CACs. Fluorescently labeled antibodies for CD11b (eBioscience #25-0112), F4/80 
(eBiosceince #12-4801), and Gr1 (eBioscience #11-5931) were used to stain for inflammatory cell 
presence in the samples. Briefly, blocking buffer (10%NGS + 1%BSA in PBS) was applied to the cell 
suspension for 15 minutes at room temperature. 0.25ug of each antibody was the applied to the individual 
cell suspensions and these were placed on ice for 45 minutes. Cells were then washed three times in PBS 
with 0.1% BSA before flow cytometry was collected with a BD LSRFortessa (Franklin Lakes, New 
Jersey) and analyzed with FlowJo software (Tree Star, Inc. Ashland, OR 
Statistical Analysis 
Data was compared using a Students unpaired t-test (two-tailed), with a p-value less than 0.05 considered 
significant. A 3-way ANOVA was used to compare contributions from and interactions between different 
test factors in in vivo experiments using IBM SPSS Software. ANOVA statistical evaluations were 
performed in consultation with a biostatistician at Harvard Catalyst. 
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2.4  Results 
OEC and CAC Characterization 
The expression of surface markers commonly used to characterize endothelial progenitors was first 
analyzed on OECs and CACs to confirm their identities (Figure 2.1A-B). Flow cytometry analysis 
confirms a high percentage of OECs expressed typical endothelial markers, including CD31, VE-
Cadherin, and VEGFR-2, a smaller percent expressed CD34, and no expression of CD45 or CD14 was 
detected. CAC populations alternatively showed moderate percentages staining positive for CD31 and 
VEGFR-2, but high percentages staining positive for CD45 and CD14, hematopoietic and myeloid 
lineage markers, respectively.  A high percentage of both OECs and CACs expressed CXCR4, the 
receptor for SDF (75% and 85%, respectively). 
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Figure 2.1. Flow cytometry characterization 
of OECs (A) and CACs (B). Representative 
histograms of relative expression of 
endothelial and hematopoietic markers used 
to characterize progenitors.  Antibody-
stained sample (black line) and isotype 
control (grey line). 
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In vitro Adhesion Models 
As adhesion of progenitors to endothelial cells in blood vessels is an important initial step in the 
recruitment of these cells, OECs and CACs were assayed for their ability to adhere to cultured human 
microvascular endothelial cells (HMVECs). When HMVECs were pre-treated with TNFα, an 
inflammatory cytokine, to mimic the inflammation typical of ischemic tissues, the expression of ICAM 
and VCAM were increased, as expected (Figure 2.2A-B). TNFα stimulation of HMVECs led to increased 
adhesion of both OECs and CACs to endothelial monolayers compared to untreated endothelial cells 
(Figure 2.2C; Suppl Figure 2.1). OEC adhesion was increased by a factor of 1.6, while CAC adhesion 
was increased by a factor of 6 with TNFα stimulation. For comparison, lymphocyte adhesion increased by 
11 times when endothelial cells were stimulated with TNFα (Figure 2.2C). Since TNFα stimulation 
causes up-regulation of adhesion molecules on the endothelial surface, and also leads to increased OEC 
and CAC adhesion, it is likely that integrin-adhesion molecule interactions are involved in this process. A 
common interaction mediating adhesion of circulating cells involves β2 integrins (αL β2 and αM β2) and 
ICAM
10,50. Almost all CACs expressed high levels of β2, while OECs were either negative or expressed 
low levels (Figure 2.2D). In addition, CACs express other integrins, such as α4, α5β1, β3, β4, and β6, to a 
greater extent than OECs (Suppl Figure 2.2). These differences may be responsible for the larger increase 
in adhesion for CACs compared to OECs following TNFα stimulation of HMVECs. β2 blocking 
antibodies, applied at saturating concentrations, reduced adhesion of both OECs and CACs in a 
statistically significant manner (Figure 2.2E-G). To further probe the role of β2 integrins, since the 
reduction in adhesion of OECs with β2 integrins blocking antibodies was modest, recombinant human 
soluble ICAM (rhsICAM) protein was added to OECs as an alternative method of blocking β2 integrins. 
The addition of rhsICAM reduced adhesion of OECs to HMVECs to the same level as β2 blocking 
antibody (82% of control; Suppl Fig 2.3). Blocking β2 integrins on CACs reduced adhesion to 40% of the 
control on non-stimulated HMVECS, and to 65% of the control with TNFα-stimulated HMVECs (Figure 
2F). Adhesion results were replicated with CACs seeded on Human Umbilical Vein Endothelial Cells 
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(HUVECs), verifying that the adhesion behavior was not specific to one endothelial cell type (Figure 
2.2G). Additionally, as a positive control, lymphocytes were also subjected to β2 blocking before 
application onto TNFα-stimulated HMVECs. Lymphocyte adhesion was reduced to 55% of the control 
level following the addition of β2 blocking antibodies (Figure 2.2H).  These results suggest that β2 
integrin is more responsible for CAC than OEC adhesion to endothelial cells. CACs may be more 
responsive to the ICAM level on endothelial cells than OECs in part because they rely on β2 integrins for 
adhesion to a greater extent than OECs. 
Finally, in order to specifically assay the β2 integrin-ICAM interaction in OEC and CAC adhesion, these 
cells were tested for their ability to adhere directly to an ICAM-coated surface (Suppl Figure 2.4 - ICAM 
deposition method verification). Similar to adhesion assays with endothelial cells, adhesion of both OECs 
and CACs was reduced when β2 blocking antibodies were added to the cells prior to seeding onto the 
ICAM surface (Figure 2.2I-J). To eliminate all integrin involvement during adhesion, EDTA was added 
to the adhesion solution.  EDTA did not reduce adhesion of OECs or CACs to a greater extent than β2 
blocking antibodies alone, suggesting that the only integrin both OECs and CACs use to adhere to ICAM 
surfaces is the β2 integrin, as expected. OECs and CACs were also added to BSA-coated wells as a 
negative control to assess the background level of adhesion to the well plate surface. OECs and CACs 
demonstrated the lowest levels of adhesion to BSA-coated wells.  
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Figure 2.2. Adhesion of OECs and CACs to endothelial cells, and role of B2 integrins. A) Immunohistochemical 
staining of ICAM and VCAM on HMVECs treated with 50ng/ml TNFα for 8 hours or control (No Stimulation). 
Scale bars are 200µm. B) Representative histograms of flow cytometry characterization of ICAM and VCAM 
expression on HMVECs after TNFα stimulation (red line) or no stimulation (black line); grey line is isotype control. 
C) Adhesion of OECs, CACs and lymphocytes to HMVECs grown in regular media (Control) or media 
supplemented with TNFα. Cell counts are normalized to the control to compare the relative increase in adhesion to 
activated endothelial cells. Inset is magnified view of OEC adhesion. D) Representative histograms from flow 
cytometry characterization of β2 integrin expression on OECs and CACs. Antibody-stained sample (black line) and 
isotype control (grey line).   
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Figure (2.2 Continued) 
 
Figure 2.2 (Continued). E-H) Adhesion of OECs to HMVECs (E), CACs to HMVECs (F), CACs to HUVECs (G), 
and lymphocytes to HMVECs (H) with and without application of a β2 integrin blocking antibody, and with or 
without TNFα stimulation of endothelial cells. I-J) Adhesion of OECs (I) and CACs (J) to surfaces coated with 
5mg/ml recombinant human soluble ICAM protein or BSA as the negative control.  2mM MnCl2 was added as the 
positive control to activate integrins, and 5mM EDTA was added to prevent integrin-based adhesion. Results were 
combined from 2-10 experiments with n=6 for each experiment. Data is plotted as Mean ± SEM. * p < 0.05 
compared to control, ‡ p < 0.05 compared to TNFα-stimulated control.  
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Effects of SDF on OEC and CAC Adhesion 
SDF is involved in endothelial progenitor trafficking and is also known to activate integrins on 
lymphocytes to increase adhesion to endothelial cells
51,52
. We therefore tested the ability of SDF to 
increase adhesion of OECs and CACs. VEGF is not expected to affect adhesion by OECs or CACs and 
was therefore not tested in these assays. SDF was presented on the surface of endothelial cells by pre-
incubating HMVECs with 500ng/ml SDF for 1 hour and was then rinsed before applying OECs or CACs.  
Alternatively, SDF was continuously present in the adhesion buffer solution during OEC and CAC 
adhesion. For OECs, SDF modestly increased adhesion only when it was presented on the surface of 
unstimulated endothelial cells. OEC adhesion was higher in all three conditions when HMVECs were 
stimulated with TNFα, and no statistically significant effect of SDF on adhesion was found in this setting 
(Figure 2.3A). In contrast, CAC adhesion to unstimulated endothelial cells increased both when SDF was 
presented in solution during adhesion (1.8X) and on the surface (2.7X, Figure 2.3B). CAC adhesion was 
dramatically increased in all these conditions following TNFα stimulation of endothelial cells, and 
adhesion of CACs was only further increased when SDF was presented in solution. 
SDF was also tested for the ability to increase OEC and CAC adhesion to ICAM surfaces. OEC adhesion 
was increased modestly with SDF, but the effect was only statistically significant when SDF was 
presented from the adhesion surface (Figure 2.3C). In contrast, CAC adhesion to ICAM-coated dishes 
doubled when SDF was present in solution (Figure 2.3D). As a positive control, MnCl2 was added to 
activate integrins, which resulted in increased adhesion of both OECs and CACs, although the effect was 
more dramatic for CACs, in agreement with the above finding that CACs express higher levels of 
adhesion-mediating β2 integrins. These results provide further support for an increased responsiveness of 
CACs, compared to OECs, to adhesive cues. 
Finally, to better mimic the in vivo process of adhesion that progenitors must undergo during recruitment, 
flow-based adhesion assays were conducted in PDMS-based parallel-plate flow channels (Suppl Figure 
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2.5). HMVEC monolayers were grown to confluence with media flowing over the surface, with a 
resulting shear stress of 0.1dyn/cm
2
. The effects of SDF on progenitor adhesion, when presented both on 
the surface and in solution during adhesion, were tested in these devices. SDF has differential effects on 
lymphocyte adhesion depending on the presentation
51
, which may also be possible to observe for OECs 
and CACs. OECs showed an increase in adhesion when SDF was presented in solution, but only surface 
presentation of SDF resulted in a statistically significant increase (Figure 2.3E). CACs demonstrated the 
same trend, where only surface presentation led to a statistically significant increase in adhesion. CAC 
adhesion was increased by 4-fold, whereas OEC adhesion was increased less than 3-fold in this assay, 
consistent with previous results where CACs showed higher sensitivity to SDF (Figure 2.3F). 
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Figure 2.3. SDF effects on OEC and CAC adhesion. A-B) Adhesion of OECs (A) and CACs (B) to HMVECs with 
SDF presented in solution during adhesion or on the surface of HMVECs. C-D) Adhesion of OECs (C) and CACs 
(D) to ICAM-coated surfaces with SDF presented in solution or on the surface. Data are presented as Mean ± SEM 
from a minimum of 3 separate experiments with n=6 for each experiment. E-F) Adhesion of OECs (E) and CACs 
(F) to HMVECs under flow conditions with SDF presented in solution during adhesion or on the surface. Shear 
stress at the surface was 0.1dyn/cm
2
 and flow velocity was 0.2mm/sec. For each experiment, 30-60 images were 
captured for each condition to quantify cell adhesion per area; each experiment was repeated three times. * p < 0.05 
compared to control, 
‡
 p < 0.05 compared to TNFα-stimulated control. 
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OEC and CAC Migration in Response to VEGF and SDF 
Migration of OECs or CACs into ischemic tissue is also an important step in the recruitment of these 
cells. VEGF and SDF were tested for their ability to promote migration of OECs and CACs in transwell 
assays. OECs demonstrated a 25% increase in migration towards a source of SDF (100ng/ml), and a 31% 
increase in migration towards VEGF (50ng/ml) (Figure 2.4A). When VEGF and SDF were presented in 
combination, each at the same concentration used individually, OEC migration doubled, suggesting a 
synergistic effect of the two growth factors. CACs demonstrated a nearly three-fold increase in migration 
when SDF was present, while VEGF had no effect on migration , and the combination of VEGF and SDF 
did not increase CAC migration significantly above the condition with SDF alone (Figure 2.4B).  
 
Figure 2.4. OEC and CAC migration toward SDF and VEGF. Quantification of relative migration in transwells 
toward 100ng/ml SDF, 50ng/ml VEGF or the combination for OECs (A) and CACs (B). Data are shown as Mean ± 
SEM from one experiment, with n = 6-10. * p < 0.05, ** p < 0.01, *** p < 0.001. 
 
VEGF and SDF Delivery System 
Hydrogels to provide a sustained and localized release of VEGF and SDF were next characterized. 
Injectable alginate gels were fabricated from a combination of 1% oxidized, low and high molecular 
weight polymer chains and were cross-linked with calcium ions
32,48
. The use of a hydrogel for growth 
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factor and cytokine delivery creates a depot for localized and sustained release
25,48
. The release kinetics of 
VEGF and SDF were individually quantified by incorporating 
125
I-radiolabeled protein into alginate gels, 
and measuring the amount released into PBS supplemented with 1% BSA at multiple time points with a 
gamma counter. SDF exhibited a burst release of ~50% gels over the period of a few days, followed by a 
continuous slow release for several weeks (Figure 2.5A). VEGF exhibited similar release kinetics, with 
faster release in the first few days and slower, steady release at later time points, as expected
48
 (Figure 
2.5B). The sustained release demonstrated by VEGF and SDF from these gels in vitro is expected to 
translate to an extended release in vivo, as was shown previously
48
.  
 
Figure 2.5. Characterization of cytokine and growth factor release from injectable alginate hydrogels. A-B) 
Cumulative release of SDF (A) and VEGF (B). Mean ± SD. 
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CACs were delivered to the bloodstream via intracardiac injection. Intracardiac injections were found to 
dramatically reduce cell accumulation in the lungs compared to tail vein injections (Suppl Fig 2.6A-B).  
Accumulation of OECs and CACs in the semimembranosus, semitendinosus, gracilis and adductor 
muscles surrounding the gel injection site was quantified 24 hours after cell delivery by retrieving muscle 
tissue, digesting to single cells, and using flow cytometry analysis (Figure 2.6A). Gel injection alone 
appeared to modestly increase the number of accumulated OECs and CACs, but not in a statistically 
significant manner. Generally, there was a trend for both OECs and CACs to accumulate to greater 
numbers in limbs treated with VEGF and SDF compared to control gel injections (Figure 2.6B-C). 
Further, the ratio of the mean number of cells accumulated in the test limb over the contralateral limb is 
always higher for the VEGF and SDF conditions versus control conditions (7.6 vs 2.2, respectively for 
OECs, and 3.6 vs 1.9 respectively for CACs). Infiltration of inflammatory cell populations into the hind-
limbs was also characterized, as VEGF and SDF are known to recruit a variety of inflammatory cells
53–57
. 
Interestingly, when CACs were delivered to the blood stream and allowed to accumulate in non-ischemic 
limbs at sites of alginate gel injection, there was a subsequent large influx of both CD11b+ myeloid-
lineage cells and F4/80+ cells, presumably macrophages, whereas extremely low inflammatory cell influx 
was observed with OEC delivery (Figure 2.6D-E). In the contralateral limb the average percentage of 
CD11b positive cells was 3% and F4/80 positive cells was 0.5%. When CACs were transplanted, 
statistically significant differences between the test limbs and contralateral limbs were found for both 
CD11b+ and F4/80+ cells, regardless of whether gels contained VEGF and SDF or were blank. No 
statistically significant differences between test limbs and contralateral limbs were found for either gel 
condition or inflammatory cell type when OECs were transplanted. There was a trend of increased Gr1+ 
cell accumulation at the gel injection site compared to the contralateral limb, but no statistically 
significant differences were found for either CAC or OEC delivery. Further, no difference in the level of 
inflammatory cell recruitment was found between limbs receiving VEGF and SDF-delivering gels and 
control gels, for either cell type.  While the number of CACs present in non-ischemic muscle varied 
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considerably between mice, the number of CACs recruited for each individual mouse strongly and 
positively correlated with the presence of CD11b+ cells (R
2
 = 0.69, Figure 2.6F), F4/80+ cells (R
2
 = 0.94, 
Figure 2.6G), and Gr1+ cells (R
2
 = 0.89, Figure 2.6H) in that particular limb. For each CAC found in the 
hind-limb, there were approximately 680 Cd11b+ cells, 220 F4/80+ cells, and 40 Gr1+ cells. Delivery of 
OECs did not result in the same strong, linear correlation for either CD11b+ cells (R
2
 = 0.44, Figure 2.6I), 
F4/80+ cells (R
2
 = 0.43, Figure 2.6J). The R
2
 value for Gr1+ cells after OEC delivery is artificially high 
(R
2
 = 0.74), because it is strongly influenced by the single data point associated with ~2500 OECs 
collected; without it, R
2
 = 0.06 (Figure 2.6K). Application of the linear correlation for each immune cell 
type would suggest that for each OEC found in the hind-limb, there were approximately 24 CD11b+ cells 
and 18 F4/80+ cells, and 0.5 Gr1+ cells, approximately 1-2 orders of magnitude fewer than for CACs.  
 
Figure 2.6. OEC and CAC recruitment to non-ischemic mouse hind-limbs with VEGF and SDF delivery. A) Flow 
cytometry plots of DiD positive cells collected from mouse hind-limb muscles where gel was injected (Test Limb) 
or from the Contralateral Limb. B-C) Quantification of the total number of OECs (B) and CACs (C) recovered from 
mouse hind-limb muscle surrounding the alginate gel injection site (test limb) or the muscle from the contralateral 
limb. 750,000 OECs or 200,000 CACs were systemically delivered into separate groups of mice. Data is shown as 
Mean ± SEM, n=4. 
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Figure 2.6 (Continued)
 
Figure 2.6 (Continued). D) Flow cytometry characterization of myeloid lineage cells (CD11b+) and F4/80+ cells 
collected from hind-limb muscle tissue surrounding the gel injection. E) Quantification of the percentage of total 
cells in the tissue surrounding alginate gel injection site that stained positive for CD11b, F4/80, or Gr1 after 
systemic injection of OECs and CACs. Mean ± SD, n=4. * p < 0.05, ** p < 0.01 
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Figure 2.6 (Continued)
 
Figure 2.6 (Continued). F-K) Plots of number of CACs or OECs collected in each limb and the percentage of cells in 
the tissue that were positively stained for CD11b, F4/80, and Gr1. Correlation plots shown, with linear-fit equation 
and R
2
 value indicated on each chart. 
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In Vivo OEC and CAC Recruitment to Ischemic Limbs 
Recruitment of OECs and CACs to ischemic muscle, in the absence of VEGF and SDF stimulation, was 
next analyzed.  Mice were subjected to complete ligation of the external iliac artery and vein in order to 
induce hindlimb ischemia (Figure 2.7A). Blood flow to the test limb was reduced to 25% of the 
contralateral limb (Figure 2.7B), as expected for this model
31,58
. Either during surgery, or on day 7 or 14 
following surgery, mice also received an injection of blank alginate (no VEGF or SDF). OECs or CACs 
were delivered on day 1, 8 and 15 post-surgery, and were allowed to accumulate in limbs for 24 hours 
before muscle tissue was collected for analysis (See figure 2.7C for timeline). The numbers of both OECs 
and CACs accumulating in the ischemic hindlimb muscle tissue were increased dramatically at Day 2 
(Figure 2.7D-E). The recruitment of OECs to ischemic limbs still remained high when cells were 
delivered on day 8 (with limbs collected on day 9), but the effect of ischemia on recruitment was lost 
when cells were delivered on day 15. Cell accumulation in the contralateral, control limb was low for all 
conditions and time points, suggesting the impact of ischemia on cell accumulation is a local effect, with 
little systemic spill-over impact (Figure 2.7F).  To qualitatively confirm results using labeled cells, 
luciferase-expressing OECs were additionally delivered on day 1 post-surgery, and analyzed using non-
invasive imaging. Preferential accumulation in the ischemic hind-limbs, compared to the contralateral 
limb, was again noted (Figure 2.7G). Additionally, immunohistochemistry was used to locate 
systemically OECs within the muscle tissue (Suppl Figure 2.7). OECs were identified within tissue 
sections, but were often difficult to find because typically 0-2 cells were present within each 10µm 
section. Although the number of cells per section was very low, it was quantitatively consistent with the 
total number of OECs collected from muscle for flow cytometry analysis being evenly distributed 
throughout the tissue volume. 
To determine if cells are simply trapped in blood vessels which may be altered in the ischemic tissue, 
OECs that had been previously fixed with 1% paraformaldehyde for 10 minutes were injected into the 
blood stream of mice one day after ischemia surgery. The accumulation of fixed cells was compared to 
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the recruitment of regular, non-fixed OECs. The average number of fixed OECs accumulated in the 
ischemic limb was lower than the average number of regular OECs, although this difference was not 
statistically significant (Figure 2.7H). As an additional test for passive accumulation in the ischemic hind-
limb, fluorescent beads with either a 6µm or 15µm diameter were systemically delivered one day 
following surgery. Quantification of 6µm bead accumulation in the hind-limb muscles revealed no 
preference for accumulation in the ischemic or contralateral, non-ischemic limb (Figure 2.7I). 
Specifically, the ratio of the number of 6µm beads found in the ischemic limb to the contralateral limb 
was 1.01 ± 0.21 (Mean ± SEM, n=5). Alternatively, the larger 15µm beads, which are approximately the 
same size as both OECs and CACs, resulted in severe injury or death to 3 out of 4 mice, most likely due 
to entrapment and blockage of vital blood vessels. The single surviving mouse showed no preference for 
bead accumulation in the ischemic or contralateral limb, while the number of beads detected was 
extremely low (approximately 30 times fewer than the number of 6µm beads found in the limbs). 
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Figure 2.7. Recruitment of progenitors to hind-limb muscle tissue after ischemia surgery. A) LDPI images of blood 
perfusion in mouse limbs before and after surgery. B) Quantification of blood perfusion before and after surgery. 
Mean ± SD, n=20. C) Experimental timeline. D) Flow cytometry plots of DiD-labeled OECs collected from mouse 
muscle in the ischemic limb (left), contralateral limb (center) and from an ischemic limb without OECs delivered 
(negative control, right). Dot plots are shown as fluorescence intensity vs. side scatter. 
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Figure 2.7 (Continued)
 
Figure 2.7 (Continued). E-F) Number of OECs and CACs accumulated in mouse hind-limbs when injected at 
various time-points after surgery in the ischemic (E) and the contralateral limbs (F). Data are shown as Mean ± 
SEM, n=6. G) IVIS images of hind-limbs of mice following systemic delivery of luciferase-transduced OECs.  Both 
the ischemic limb (left) and contralateral limb (right) are shown (left image), and hind-limbs from a control mouse 
which underwent surgery but did not receive OECs (right image). H) Quantification of OEC accumulation on day 2 
in the ischemic and contralateral limbs after delivery of regular or paraformaldehyde-fixed cells Mean ± SEM, n=10. 
I) Number of 6µm-diameter fluorescent beads accumulated on day 2 in the ischemic and contralateral limbs. Mean ± 
SEM, n=10. 
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As ischemia surgery is expected to lead to inflammation
59
 (Figure 2.8A), immune cell infiltration into the 
ischemic tissue following hind-limb ischemia surgery was characterized. A dramatic influx of cells was 
observed within two days (Figure 2.8B-D), and CD11b+ myeloid lineage cells constituted approximately 
half of the total cells collected from the ischemic limb at this time (Fig. 2.8E). The number of CD11b+ 
cells remained high at day 9, and decreased at day 16. F4/80+ cells, presumably macrophages, were also 
present in large numbers early, and showed a reduced presence over time (Figure 2.8F). Cells positive for 
Gr1 accumulated to significant numbers at day 2, but returned close to baseline by day 9 (Figure 2.8G). 
The number of inflammatory cells in the contralateral limb remained very low at all time points. 
Specifically, CD11b+ cells ranged from 5-10%, F4/80+ cells decreased from 7% on day two to 1.4% on 
day 16, and Gr1+ cells decreased from 1.4% to 0%, which were almost all significantly less than the 
measured values for the ischemic limb.  Last, the kinetics of inflammatory cell accumulation in the 
ischemic tissue was similar to that observed with infused OECs (Fig. 2.7E). 
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Figure 2.8. Characterization of inflammatory cell infiltration due to ischemia. A) Photograph of ischemic, swollen 
limb two days after surgery (left) and the contralateral, healthy limb (right). B) Cell accumulation, as analyzed using 
DAPI-stained tissue sections from the ischemic limb compared to the contralateral, healthy limb. Scale bars are 50 
C) Average number of cells collected from ischemic and contralateral limbs two days after surgery. Mean ± SEM, 
n=12. D) Flow cytometry plots for analysis of CD11b, F4/80 and Gr1 stained cells collected from ischemic and 
healthy limbs (contralateral) two days after surgery. Blue is unstained; Red is antibody stained. 
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Figure 2.8 (Continued)
 
Figure 2.8 (Continued). E-G) Time course quantification of the percentage of cells in both the ischemic limb, and 
contralateral, control limb that stained positive for CD11b (E), F4/80 (F), and Gr1 (G) as a function of time. Mean ± 
SD, n=6. * p < 0.05. 
 
SDF and VEGF-releasing Alginate Hydrogels for OEC and CAC Recruitment to Ischemic Limbs 
Since OEC recruitment to ischemic limbs is highest immediately after surgery, this time point was chosen 
to test whether VEGF and SDF-releasing alginate gels could enhance recruitment of OECs and CACs. 
Similar to the timeline shown in Figure 2.7C, some mice underwent hind-limb ischemia surgery 
immediately before receiving an intramuscular injection of alginate gel containing VEGF and SDF, or a 
control gel without growth factors. One day following surgery, OECs or CACs were delivered into the 
circulation, and 24 hours later muscle tissue was collected and analyzed.  OEC accumulation in both 
ischemic muscle and non-ischemic muscle was modestly increased with VEGF and SDF releasing gels, 
while CAC accumulation approximately doubled with VEGF and SDF delivery (Figure 2.9A). A 3-way 
ANOVA (3 factors: Cell Type, Treatment, Ischemia; 2 levels: OECs vs. CACs, VEGF+SDF vs. Control, 
and Ischemia vs. Non-Ischemic) was used to compare differences between conditions, as well as 
determine if there were interactions between factors. Full-factorial analysis showed that all possible 
interactions between pairs of factors were not statistically significant (Cell Type * Treatment: p=0.317; 
Cell Type * Ischemia: p=0.863; Treatment * Ischemia: p=0.977). Interaction effects were then excluded, 
and a 3-way ANOVA of the main effects was performed (Suppl Table 1). By this analysis, significant 
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differences were found between the recruitment of CACs and OECs (p=0.022), as well as the effect of 
VEGF and SDF gels compared to control gels (p=0.050, Figure 2.9B and Suppl Table 2.1). Lastly, we 
quantified inflammatory cell infiltration in muscle with VEGF and SDF delivery.  There was a trend 
towards increasing accumulation of inflammatory cells with VEGF/SDF delivery, but the only 
statistically significant difference was in accumulation of F4/80+ cells at day 2 (Figure 2.9C-E). 
 
Figure 2.9. OEC and CAC recruitment, and inflammatory cell infiltration, into ischemic and non-ischemic limbs 
with VEGF+SDF delivery via alginate gels. A) Percentage of total transplanted cells recruited to hind-limbs after 
injection of alginate gels releasing VEGF and SDF or control gels (no growth factors). Gels were injected into non-
ischemic, healthy limbs (n = 4) and in separate mice, gels were injected into hind-limbs following ischemia surgery 
(n = 6). Mean ± SEM. B) P-values from 3-way ANOVA Regression Analysis of main effects of Cell Type, 
VEGF+SDF treatment, and Ischemia (See Supplemental Table 2.1). * p <0.05. C-E) Percentage difference between 
the total cells in ischemic muscle tissue from animals treated with VEGF+SDF gel condition normalized to 
untreated ischemic limbs, that stained positive for CD11b (C), F4/80 (D) and Gr1 (E).  Mean ± SD, n=6. * p < 0.05. 
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2.5  Discussion 
The data from these experiments together demonstrate that the targeting efficiency of circulating 
endothelial progenitors to ischemic tissue in vivo can be enhanced by local delivery of VEGF and SDF, 
which were shown to affect the adhesion and migration of these cells in vitro. Specifically, CACs 
adhesion was more responsive to HMVECs that have been activated by TFNα in static in vitro adhesion 
assays compared to OECs, likely due to differences in β2 integrin expression on each progenitor cell type. 
SDF presented on the surface of HMVECs significantly increased adhesion of both OECs and CACs in 
flow-based adhesion assays. SDF also enhanced migration of CACs, while the combination of VEGF and 
SDF increased migration of OECs to a greater extent than either factor alone. These in vitro results led us 
to investigate the potential of local, sustained presentation of VEGF and SDF to increase recruitment of 
OECs and CACs to both ischemic and non-ischemic muscle tissue in a mouse model.  Local delivery of 
VEGF and SDF from alginate gels increased accumulation of both cell types, as compared to control gels, 
in a statistically significant manner as indicated by 3-way ANOVA.  A similar trend, in terms of enhanced 
accumulation, was noted in both ischemic tissue and normal tissue. Further, CACs accumulated to a 
greater extent than OECs across all conditions. Entrapment of OECs within vessels of the ischemic tissue 
accounted for approximately half of the total cell accumulation in the limb. This is likely similar for 
CACs, since their size is comparable to OECs. Overall, the fraction of transplanted OECs or CACs 
recruited to ischemic tissue was extremely low for all conditions, highlighting the inefficiency of this cell 
delivery method, even with use of recruitment signals. Lastly, the effect of VEGF and SDF on 
inflammatory cell infiltration into ischemic and normal tissue was also quantified.  Ischemia alone led to 
significant infiltration of CD11b+, F4/80+, and Gr1+ cells from days 2-16. VEGF and SDF gels only 
increased F4/80+ cell accumulation in ischemic limbs at day 2, although not at days 9 and 16, and did not 
alter immune cell infiltration in non-ischemic limbs. Quite interestingly, CAC accumulation at the gel 
injection site in non-ischemic limbs induced a significantly higher level of immune cell infiltration 
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compared to OECs. The number of CACs in the muscle tissue was also strongly correlated with the 
percent of CD11b+, F4/80+ and Gr1+ cells.  
In vitro adhesion assays demonstrated that TNFα stimulation of endothelial cells significantly increased 
adhesion of both OECs and CACs, although to a much greater extent for CACs.  This larger increase in 
adhesion for CACs correlated with higher surface expression of integrins involved in adhesion processes 
for other types of circulating cells, including β2 and α4 integrins50. Studies with CD34+ cells 
demonstrated that both β2 and α4 integrins play a role in adhesion to endothelial cells18, but α4 integrin is 
not expressed on OECs, therefore only the effect of β2 integrin on adhesion was examined. Addition of 
β2 blocking antibodies reduced CAC adhesion close to the level of reduction shown for lymphocytes, 
while OEC adhesion was only minimally reduced. OEC adhesion remained high after blocking β2 
integrin, likely because OECs develop other adhesive interactions with endothelial cells, possibly through 
PECAM. Although both OECs and CACs are isolated from the blood, these results suggest that CACs 
exhibit adhesion behavior more similar than OECs to a typical blood leukocyte, and are therefore likely 
more responsive to activation by chemokines.  
The effect of SDF on adhesion behavior of OECs and CACs was demonstrated using both static and flow-
based in vitro assays. SDF was presented both on the surface of endothelial cells and in solution during 
adhesion. These conditions were chosen to replicate possible modes of SDF exposure to progenitor cells 
in vivo. The shear force on the cells in the flow assays was lower than physiological shear levels 
(0.1dyn/cm
2
 vs. 1dyn/cm
2
), but this was necessary to allow cells to come into contact with the flow 
chamber surface and is comparable to the shear used in other studies
50,51,60
. Similar to the paradigm for 
chemokine exposure effects on adhesion of lymphocytes and CD34+ cells, in which surface presentation 
of SDF activates β2 integrins to a pro-adhesive, extended state18,51,61, surface presentation of SDF led to a 
significant increase in adhesion of both OECs and CACs to unstimulated endothelial cells in both static 
and flow-based assays. CACs were shown to be more responsive than OECs to SDF in the static assay, 
while in the flow assay both cell types demonstrated a similar response. Adhesion also increased slightly 
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when SDF was present in solution, although this was not statistically significant for either cell type. 
CD34+ cells in flow-based adhesion assays show increased adhesion for both modes of SDF exposure, 
with a greater effect when the chemokine was surface-presented, similar to the results shown here
18–20
. 
This behavior is contrasted with lymphocytes, where presentation of soluble SDF activates β2 integrins to 
a ‘high-affinity state’, which, contrary to the name, does not promote adhesion to endothelial cells 
(specifically when the cells are pre-exposed and then the source of SDF is removed)
51
.  My finding that 
soluble SDF did not significantly enhance OEC or CAC adhesion suggests that β2 integrins on 
endothelial progenitors may be activated to this high affinity state, in a similar manner as lymphocytes, 
but in this case the SDF source was not removed. The small effect of soluble SDF on OEC/CAC adhesion 
may be caused by SDF in the media adsorbing to the surface of the endothelial cells, although this was 
not measured in these assays. When progenitors are placed on top of TNFα stimulated endothelial cells in 
static assays, in contrast, adhesion increased when SDF was present in solution, although this was only 
significant for CACs. It’s likely that no effect was observed with surface presentation of SDF for OECs or 
CACs because the amount of SDF adsorbed to the endothelial surface relative to the high expression of 
ICAM was too low to cause a change in adhesion. Overall, the results from these in vitro assays 
demonstrate that SDF exposure can increase adhesion of both cell types, and suggest the possibility that 
OECs and CACs may be responsive to SDF stimuli in vivo.  
Migration of OECs and CACs towards VEGF and SDF was assessed in transwell assays, as a model of 
the second step in the recruitment process. CACs only migrated significantly in response to SDF, while 
the combination of VEGF and SDF enhanced OEC migration more than either factor alone. These results 
are in agreement with previous research demonstrating that SDF is a known chemoattractant for many 
circulating cell types, including CD34+ cells, and VEGF is a chemoattractant for endothelial cells
19,24,31,62–
66
.  VEGF and SDF together have a substantial synergistic effect on OEC migration. It is possible that this 
combination may influence in vivo recruitment of OECs primarily through migration, and compensate for 
the slightly lower responsiveness of these cells to adhesive cues. Transwell assays do not mimic the in 
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vivo environment in which progenitors would be migrating out of a blood vessel, but they do provide a 
simple method to determine which cytokines and combinations of cytokines can exert chemotactic effects 
on OECs and CACs. A more relevant and quantitative model would include the ability to assay effects of 
flow on a cell’s ability to migrate, the role of chemokine gradients (rather than just concentration) on 
migration
67
. A better model might also include an endothelial monolayer for the progenitors to migrate 
through, or may replicate the 3D tissue environment in which cells migrate after extravasation from a 
blood vessel
19,66,68
. (Please see Appendix D for a summary of other systems which were modeled or used 
to various degrees for assaying OEC migration.) While VEGF and SDF have differential effects on 
adhesion and migration of OECs and CACs, the in vitro data together imply that this combination of 
factors displays potential to effect recruitment of both cell types in vivo. 
OEC and CAC accumulation in vivo was significantly increased with local presentation of VEGF and 
SDF. The injectable alginate hydrogels, capable of providing sustained release of VEGF and SDF, have 
previously been measured to yield approximately 100ng/ml VEGF in hind-limb tissue at the 48 hour time 
point analyzed here, when used in this same animal model
48
. SDF has similar release characteristics as 
VEGF, and is therefore also assumed to be present in a significant concentration in vivo. A statistically 
rigorous 3-way ANOVA demonstrated that, overall, VEGF and SDF delivery had a significant effect on 
the accumulation of progenitors in muscle tissue at this time point. A similar trend was seen in both 
ischemic and non-ischemic muscle, with an approximate 2-fold increase in progenitor accumulation with 
VEGF and SDF delivery. To achieve statistically significant comparisons within each group (e.g. CAC 
delivery in non-ischemic limbs, control vs. VEGF/SDF delivery), due to the high variance associated with 
this experimental method, experiments would have required 24-70 mice per condition, and so were not 
performed. The results of these in vivo experiments are in agreement with the increased adhesion and 
migration of progenitors found with VEGF and/or SDF treatment in vitro. Finally, ANOVA analysis 
revealed that CACs accumulated to a significantly greater extent in vivo than OECs, in agreement with 
the increased responsiveness of CAC adhesion to the inflammatory state of HMVECs and to SDF 
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presentation in vitro. Although CACs were only responsive to SDF, and not VEGF, in vitro, the effect of 
SDF delivery alone was not evaluated in vivo. Based on in vitro results, CACs would be expected to 
accumulate to a similar extent with SDF delivery alone, while OEC accumulation may decrease slightly. 
Also, my findings for the effects of SDF are in agreement with previous recruitment experiments 
performed with CD34+ cells
19,54,63,69
. Many past studies use histologic analysis to identify progenitors in 
the tissue of interest, and often focus on cell location rather than quantitative evaluation
56,69,70
. While 
identification of fluorescently labeled progenitors was possible, results are likely sensitive to the 
experimental timeline. Alginate gels, alternatively, are capable of sustained cytokine release over a longer 
time period. In this study, only one experimental timeline between gel injection and cell infusion (24 
hours) and tissue collection (another 24 hours) was investigated, but at multiple time points following 
ischemia. This study did not evaluate the length of time over which the VEGF and SDF were present in 
sufficient concentration to affect cell recruitment. Clinically, if VEGF and SDF are released slowly and 
remain active over a long time period, it could be possible to have one gel injection, with multiple cell 
infusion treatments at different time points.  Lastly, while a number of studies have examined biological 
interactions between VEGF and SDF, the use of these cytokines in combination for the recruitment of 
endothelial progenitor cells has not been investigated
71–74
. 
Ischemia alone led to a significantly higher accumulation of OECs and CACs in ischemic limbs compared 
to the contralateral, control limbs. OECs that had been previously fixed in paraformaldehyde also 
accumulated to a greater extent in ischemic tissue, although only to ~1/2 the level found with viable cells, 
suggesting that physical changes in the vascular network of the ischemic muscle play some role in the 
increased accumulation of cells in this condition.  It is important to note that while a statistically 
significant increase in accumulation of viable OECs was found in the ischemic limb compared to the 
contralateral limb, this difference was not statistically significant for fixed OECs. Since fixed cells cannot 
use integrin-adhesion molecule interactions for recruitment, accumulation must occur by entrapment. 
6μm beads accumulated equivalently in the ischemic and contralateral limbs, suggesting that blood vessel 
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diameter is not reduced to below 6μm. Alternatively, 15μm beads, similar in size to OECs and CACs, 
resulted in paralysis or death of the animals, which was not too surprising since a typical capillary is 5-
10μm in diameter50. In addition to size affecting cell accumulation, viable cells are more pliable than 
beads. Paraformaldehyde treatment cross-links cell proteins and likely stiffens the cell, which in turn 
could increase the number accumulated in ischemic tissue. Further, it may still be possible for a cell that 
is physically entrapped to exert a therapeutic effect
75,76
. These cells can secrete angiogenic factors and 
contribute to new blood vessel growth through a paracrine mechanism
24,77
, and once physically entrapped 
in a capillary may be more responsive to migratory and regenerative cues presented from the gels. For 
example, VEGF exposure on OECs trapped in capillaries could activate these cells to directly participate 
in new blood vessel growth. Overall, while a significant fraction of delivered cells were trapped in 
ischemic limbs, rather than actively recruited, both modes of accumulation may permit endothelial 
progenitor participation in blood vessel regeneration. 
The effects of ischemia and VEGF/SDF delivery on immune cell infiltration of muscle were also assessed 
in these studies. Ischemia caused a significant increase in the overall cell number, a large fraction of 
which was inflammatory cells, including CD11b+, F4/80+ and Gr1+ cells. These cells, likely myeloid 
lineage cells (CD11b), macrophages (F4/80), and granulocytes (Gr1, most commonly neutrophils in this 
setting), are recruited in response to injury and hypoxia resulting from ischemia
59,78,79
. They are highly 
responsive to cytokines, including VEGF and SDF, and also secrete a variety of cytokines which help 
repair and restore damaged tissues
78,80–82
 . The presence of these cells peaked at day 2, and then decreased 
over 2 weeks. This is in agreement with the expected time course for immune cell infiltration after an 
acute ischemic injury
83,84
. Interestingly, the time course of OEC accumulation into ischemic limbs was 
similar. Delivery of VEGF and SDF gels at various time points after ischemia surgery only had an effect 
on the infiltration of F4/80+ cells at day 2, and not on later days. It is likely that signaling from the 
exogenously delivered VEGF and SDF was overwhelmed by the multitude of cytokines secreted in 
response to ischemia
80
. Inflammatory monocytes, which likely comprise a large fraction of the CD11b+ 
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population, for example, traffic mainly in response to Monocyte Chemoattractant Protein-1 following 
ischemia
85–87
. VEGF and SDF also did not affect immune cell infiltration into non-ischemic limbs. Most 
often, studies on cytokine influence on immune cell infiltration into biomaterials typically use 
immunohistochemistry to identify various cell populations
57,88,89
. Using this kind of analysis for my 
studies may have revealed local differences in cell recruitment due to VEGF and SDF delivery, as has 
been shown previously
57
. Alternatively, the flow cytometry analysis used here assessed the total cell 
population present throughout the entire muscle. The muscle tissue was collected and fully digested, with 
only some pieces of ligament not passing through a 40µm filter in the final processing step. This method 
is sensitive for the detection of low cell numbers, but again, has high variability between samples. Taken 
together, these results demonstrated that ischemia plays a large role in the infiltration of immune cells into 
muscle tissue, while VEGF/SDF delivery has a lesser impact.  
Remarkably, the systemic delivery of CACs in non-ischemic mice resulted in significant accumulation of 
CD11b+ and F4/80+ cells in the site of gel injection in the hind-limb muscle. Again, inflammatory cell 
accumulation was not dependent on whether mice received either VEGF+SDF or control gel injections. 
The number of CD11b+, F4/80+ and Gr1+ cells accumulated in the muscle strongly correlated to the 
number of CACs in the tissue. Each CAC present in the hind-limb muscle was associated with 680 
CD11b+ cells, 220 F4/80+ cells, and 40 Gr1+ cells.  While cause and effect were not established in these 
studies, CACs may secrete cytokines that enhance immune cell infiltration or activate an inflammatory 
response. Endothelial progenitors are most often assayed for secretion of angiogenic factors (VEGF, 
PDGF, FGF, HGF, IL-8, etc.), but have also been shown to secrete factors that attract monocytes and 
macrophages (MCP-1 and MIP-1), as well as other inflammatory cytokines (IL-12, IP-10)
24,77,90,91
. 
Strikingly, no increase in immune cell infiltration was observed with systemic OEC delivery, even though 
they also secrete IL-8, IL-12, and IL-6
24
.  Surprisingly little has been published demonstrating cause and 
effect of specific cytokines secreted from delivered CACs (or OECs) on the inflammatory or angiogenic 
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environment. My experiments suggest that the cytokines secreted from a very small number of recruited 
cells can dramatically influence the inflammatory state of the tissue.  
In summary, these studies demonstrate that accumulation of transplanted endothelial progenitors can be 
enhanced using local delivery of VEGF and SDF.  The efficiency of cell accumulation, even in the 
optimal conditions, was extremely low for both cell types. However, as was observed with CAC 
transplantation studies, the local accumulation of a few cells can be correlated with a substantial influence 
on the local biology. Even modest improvements in the delivery of endothelial progenitor cells to 
ischemic tissue therefore may have a therapeutic effect on blood vessel growth and regeneration. The 
following chapter examines the potential contributions of OECs and CACs to new blood vessel growth, 
and the effect of VEGF and SDF on those contributions. 
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CHAPTER 3:  
Endothelial Progenitor Cell Contribution to New Blood Vessel 
Growth and the Effects of VEGF and SDF 
 
3.1  Purpose of Chapter 
This chapter addresses the hypothesis that Outgrowth Endothelial Cells (OECs) and Circulating 
Angiogenic Cells (CACs) have distinct roles in contributing to angiogenesis, which can be altered by the 
presence of Vascular Endothelial Growth Factor (VEGF) and Stromal Cell-Derived Factor (SDF). To 
address this hypothesis, I used a 3-dimentional, in vitro sprouting assay as a model to understand the 
potential contributions to angiogenesis by OECs and CACs that have been exposed to VEGF and SDF. 
Further, I demonstrated the functional ability of VEGF+SDF-recruited OECs and CACs to restore 
perfusion in vivo. This chapter fits into the overall hypothesis of this thesis by examining if VEGF and 
SDF promote progenitor cell contribution to new blood vessel growth. 
 
3.2  Introduction 
Since the discovery of endothelial progenitor cells, interest in using these cells therapeutically for various 
forms of cardiovascular disease has grown
1–5
. However, the mechanism(s) by which endothelial 
progenitors contribute to new blood vessel growth is unclear. Early reports revealed that infused 
progenitors could be located in ischemic tissue at sites of new blood vessel growth, suggesting direct 
participation in vessel formation
1,6
.  However, years of follow-up research revealed that ‘endothelial 
progenitors’ used by different researchers were actually several distinct cell types, which could underlie 
the many discrepancies between various studies utilizing these cells. Outgrowth Endothelial Cells (OECs) 
and Circulating Angiogenic Cells (CACs) are two types of ‘endothelial progenitors,’ however, these two 
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cell types appear to differ in how they can contribute to new blood vessel growth
7
. Only OECs 
demonstrate high proliferative capacity and the ability to directly form new blood vessels, while CACs 
resemble monocytes and secrete many cytokines, which may act in a paracrine fashion on resident 
endothelial cells (See Chapter 1 for more information on these cell types)
7
.  This chapter uses in vitro 
assays to clarify the roles of OECs and CACs in contributing to angiogenic sprouting. In addition, as the 
previous chapter demonstrated that Vascular Endothelial Growth Factor (VEGF) and Stromal Cell-
Derived Factor (SDF) can impact adhesion and migration of OECs and CACs, their effect on the 
angiogenic potential of these cells in vitro and in vivo were studied.  
The sprouting assay used in these studies replicates the initial stages of angiogenesis, including the 
loosening of inter-endothelial contacts and vessel destabilization, followed by endothelial cell migration 
and the formation of sprouts, similar to the in vivo process
8
. This assay uses endothelial cell-seeded beads 
suspended in a 3D fibrin matrix, and can be used to study the dynamics of endothelial cell interactions 
and relationships between tip cells and stalk cells, and key cell signaling events
9,10
. Multiple cell types can 
be combined to study direct cell-cell interactions, and this assay can be used to study angiogenic effects of 
secreted cytokines from support cells
11,12
. Qualitative interactions between mature endothelial cells and 
OECs and CACs have been previously reported, but not a quantitative analysis
12
. Further, sprouting 
assays can be used to determine the potency of externally applied angiogenic factors, and are often 
predictive of the in vivo response to those factors
11,13,14
. Here, I used the sprouting assay to determine the 
effect of VEGF and SDF on endothelial cell sprouting. The effect of VEGF concentration, spatial and 
temporal gradients on sprouting of mature endothelial cells has previously been explored
13,14
. A minimum 
level of VEGF is necessary for endothelial cells to participate in sprouting angiogenesis in vitro and in 
vivo
13,14
. Data supporting a direct angiogenic role for SDF mainly comes from studies of endothelial cell 
tube formation on 2D matrigel surfaces, while a variety of other studies suggest that SDF indirectly 
promotes angiogenesis by regulating trafficking of various stem and progenitor cells to sites of new vessel 
growth
15–20
. A direct effect of SDF on sprouting angiogenesis has not been reported, nor has the impact of 
a combination of VEGF and SDF. Lastly, the effect of VEGF and SDF on the profile of secreted factors 
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from endothelial progenitors was measured to determine if exposure to these factors enhances endothelial 
sprouting in a paracrine manner. 
The regenerative capacity of OECs and CACs accumulated in ischemic hind-limbs and exposed to VEGF 
and SDF was also demonstrated in an in vivo model. In this model, OECs or CACs were systemically 
delivered following surgery, and preferentially accumulated in the ischemic tissue (as shown in Chapter 
2). Perfusion was then measured to quantify functional blood vessel regeneration over time. This model 
has been used to test the angiogenic strength of growth factors and other molecules delivered from 
polymer scaffolds
10,13,21–23
. Angiogenic factors that showed potency in in vitro sprouting assays 
correspondingly showed improved perfusion in vivo
11,13,14
.  OECs and CACs have also previously 
demonstrated therapeutic efficacy in this model when delivered locally from a alginate scaffold
12
. Here, 
the baseline perfusion recovery with VEGF and SDF-loaded alginate gels was quantified, and then OECs 
or CACs were infused to determine if there were additive regenerative capabilities. 
 
3.3  Materials and Methods 
OEC/CAC Cell Isolation and Culture 
As described in Chapter 2, human cord blood was used for OEC/CAC isolation within 12 hours from 
collection. Cord blood was diluted 1:1 with Hanks Balanced Salt Solution (HBSS) and gently placed on 
top of Histopaque 1077 (Sigma #10771-500ml). Samples were centrifuged at 740g (OECs) and 400g 
(CACs) for 30 minutes with no brake. Mononuclear cells were then collected and washed with HBSS. 
Remaining red blood cells were lysed and cells were washed twice with HBSS. For OEC isolation, cells 
were resuspended in EGM-2MV (Lonza #CC-3202) supplemented with 10% FBS and plated on Collagen 
coated dishes (BD #354400). Media was changed after two days, and every day until colonies appeared 
(day 10-14). Colonies were replated and maintained in EGM-2MV media while in use; OECs were used 
between passages 2 and 6. For CAC isolation, cells were plated on fibronectin-coated dishes (BD 
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#356008) in EGM-2MV without hydrocortisone and supplemented with 10% FBS. Additional media was 
added to the cells on day 4, and attached cells at day 7 were immediately used for experiments. 
Human Microvascular Endothelial Cells (HMVECs, Lonza # CC-2543) and Human Umbilical Vein 
Endothelial Cells (HUVECs, Lonza # C-2517A) were cultured in EGM-2MV from Lonza and EGM-2 
(Lonza # CC-3162), respectively, and were used between passages 3 and 6. 
Collection of Conditioned Media and Analysis 
OECs and CACs were rinsed thoroughly with PBS to remove all growth factors included in the culture 
medium. 5ml of EBM-2 (Lonza #CC-3156) containing 0.5% FBS was added per 75cm
2
, and cells were 
allowed to condition the media for 48 hours at 37
o
C in 5% CO2. Conditioned media was collected and 
immediately used for analysis or frozen and stored at -20
o
C. Secreted cytokines were measured using a 
human angiogenesis array according to the manufacturer’s protocol (Affymetrix TransignalTM 
Angiogenesis Antibody Array # MA6310). Briefly, membranes arrays were soaked for 1 hour at room 
temperature with the provided blocking buffer, followed by 3 rinses with the provided Wash Buffer II. 
Arrays were then soaked with 2ml of conditioned media at room temperature for 2 hours, with slow 
shaking, followed by three 5 minute rinses with Wash Buffer I and one 5 minute rinse with Wash Buffer 
II (standard washing method). The provided primary, biotin-conjugated antibodies were then applied to 
the arrays and incubated for two hours at room temperature with slow shaking, followed by the standard 
washing method. The provided streptavidin-HRP working solution was then prepared and 2 ml were 
added to each array and incubated at room temperature for 60 minutes, followed by the standard washing 
method. Equal volumes of Detection Buffers A and B were then mixed and added to each array for 5 
minutes at room temperature. Excess Detection Buffer mixture was then removed and arrays were imaged 
with a chemiluminescent imaging system (FluorChem
TM
 M Imager, ProteinSimple, San Jose, CA) with 
increasing exposure times until sufficient signal was detected. Array images were analyzed and quantified 
using ImageJ software. ELISA Development Kits were purchased from Peprotech for cytokines that were 
78 
 
detected with the Angiogenesis Array, including FGFb (#900-M08), IL-12 (#900-M96), IL-8 (#900-
M18), VEGF (#900-M10), PlGF (#900-K307), and Leptin (#900-K90). ELISA plates were developed 
according to manufacturer’s protocols. Briefly, capture antibodies were applied to high-bind well plates 
(Nunc Maxisorp #439454) and allowed to adsorb overnight at room temperature. After rinsing wells, 
standards and conditioned media samples were then added to individual wells in duplicate, and incubated 
at room temperature for 2 hours. Samples were then aspirated and plates were washed four times with 
0.05% Tween in PBS. Detection Antibody was then applied to each well and allowed to incubate for two 
hours at room temperature, followed by washing as described previously. Avidin-HRP conjugate was 
then applied to each well for 30 minutes at room temperature, followed by application of ABTS Liquid 
Substrate Solution (Sigma # A3219). Color development was monitored and absorbance at 405nm and 
650nm was read every 5 minutes with a plate reader until sufficient color developed (Bio-Tek Synergy 
H1 Plate Reader, Winooski, VT). 
Sprouting Assays 
Sprouting assays were performed similarly to those previously described
13,14,24
. Here, HMVECs, 
HUVECs or cord blood-isolated OECs between passage 2 and 6, or CACs, were seeded onto collagen-
coated dextran beads (Cytodex
TM
3 Microcarriers, GE Healthcare # 17-0485-01) that were approximately 
200µm in diameter. In some conditions, OECs were stained with octadecyl rhodamine B chloride dye 
(Life Technologies #O-246) overnight at 1nM and seeded onto beads in a 1:1 ratio with unstained 
HMVECs or HUVECs. Cells were trypsinized from a T75 flask, and added to a small spinner flask with 7 
ml of growth media and beads. The spinner flask was placed in an incubator at 37
o
C on a stir plate and 
alternated between 2 minutes spinning at 60rpm and 28 minutes at rest for 4 hours, followed by 20 hours 
spinning at 60rpm. Cell-seeded beads were then transferred into T25 flasks with fresh media and placed 
on an orbital shaker until cells became confluent. For conditions with rhoadimine –stained OECs and 
unstained HUVECs or HMVECs co-seeded on the beads, the percentage of each cell type on the beads 
was measured by flow cytometry prior to beginning assays (BD LSRFortessa, Franklin Lakes, New 
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Jersey). 1ml of bead suspension was then gently mixed with 3ml of 2mg/ml fibrinogen (Millipore #EMD 
341576) and 400µl of 500µg/ml aprotinin (Sigma #A4529-5MG) in a 15 ml tube. 250µl of this 
fibrinogen-aprotinin-bead solution was then gently mixed with 200µl of a 2U/ml thrombin (Sigma 
#F3879-250MG) solution in a 24 well plate to form a fibrin gel. Gels were allowed to solidify in the 
incubator at 37
o
C for 10 minutes. 600µl of media was gently added on top of the fibrin gel (EBM2 + 5% 
FBS was used as the control media, with SDF = 100ng/ml, VEGF = 50ng/ml, or the combination added as 
test conditions). Media was changed every 24 hours for 3 days. Increasing, stable, and decreasing profiles 
of SDF (10-100-190ng/ml on day 1-2-3, or 100-100-100ng/ml, or 190-100-10ng/ml, respectively) were 
also overlaid on top of a decreasing VEGF profile (95-50-5ng/ml) to test for effects of temporally-
controlled cytokine presentation on sprouting. Alternatively, 50,000 OECs or CACs in 600µl of control 
media were seeded on top of fibrin gels containing HUVEC-covered beads to assay for angiogenic effects 
of secreted cytokines. Polyclonal antibodies were also applied to wells containing OECs or CACs on top 
of the fibrin gel to block secreted cytokines. PlGF (Peprotech #500-P226 ), FGFb (Peprotech #500-P18), 
IL-8 (Peprotech #500-P28), and Leptin (R&D Systems #44802) antibodies were used at 1, 0.4, 0.2, and 
2µg/ml, respectively, and were reapplied in fresh control media every 24 hours for 3 days. At 24, 48 or 72 
hours, fibrin gels were rinsed twice with PBS and then 4% paraformaldehyde in PBS was added to fix the 
cells. Plates were stored at 4
o
C until quantification. The number of sprouts per bead was counted on a 
Zeiss Axio Observer Z1 microscope (Zeiss, Thornwood, NY). A sprout was defined as more than one cell 
protruding from the bead while remaining connected to the bead surface, as previously described
13,24
. 
Approximately 200 beads per well were counted, with n = 4 wells per condition. 
Time Lapse Imaging of OEC Sprouting 
Sprouting assays were prepared as described above. A 24-well plate of OEC-seeded beads in fibrin gel 
was then placed in a live-cell imaging chamber on a Zeiss Axio Observer Z1 microscope, pre-warmed to 
37
o
C and set to 5% CO2. Metamorph Imaging Software (Molecular Devices, Sunnyvale, CA) was used to 
set up the time lapse image capture. 200µm stacks (10µm steps) of phase contrast images over ten fields 
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of view, each containing one cell-seeded bead, were imaged per well, with 4 wells imaged per condition 
(120 positions total for 3 conditions). Image stacks were captured every 20 minutes for 24 hours. For each 
bead, the time at which the first OEC protruded from the bead was recorded as the sprout initiation time. 
The number of sprouts per bead at 8 hours was also quantified. 
Alginate Gel Preparation 
Gels were prepared as previously described
14,23
.  In brief, Ultra-pure MVG alginate was obtained from 
Pronova (# 4200106). MVG alginate was irradiated at 3MRad to obtain low molecular weight polymer 
chains. 1% of carboxylic acid groups on both high and low molecular weight alginates were oxidized to 
aldehyde groups with sodium periodate, to produce a hydrolytically labile polymer backbone
25
. The 
reaction was stopped with the addition of ethylene glycol after 17 hours. Alginate polymers were then 
dialyzed in 3000MWCO membranes for 3 days with repeated water exchange, frozen and lyophilized for 
storage. One day prior to use, both HMW and LMW alginate were reconstituted with EBM-2 to 2%w/v. 
VEGF and SDF were then added to a mixture of 75% LMW and 25% HMW alginates. 40µl of 0.21g/ml 
CaSO4 was added per 1ml of alginate to crosslink the gel, and the solution was mixed between two 1ml 
syringes connected with a Leur-Lok union. Gels were allowed to crosslink for at least 30 minutes prior to 
use. 
Hind-limb Ischemia Model 
All animal experiments were performed in accordance with IACUC approved protocols. Hind-limb 
ischemia surgery was performed on C57BL6/J mice (Jackson Laboratories #000664) or C.B-17 SCID 
mice (Taconic #CB17SC-F) less than 10 weeks old, as previously described
13,23
.  Briefly, mice were given 
an intraperitoneal injection of a Ketamine/Xylazine cocktail to induce anesthesia. An incision was then 
made at the inner thigh, exposing the underlying muscle and the external iliac artery and vein, and the 
hypogastric artery and vein. Two ligatures were placed around the external iliac artery and vein and one 
was placed around the femoral artery and vein. The external iliac vessel was cut between the two suture 
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knots. Alginate gels containing 2ug of SDF, 3ug of VEGF, the combination or control gels (no factors) 
were then injected intramuscularly under the ligation site. The incision was closed with 7mm staples. 
Mice were imaged with a Laser Doppler Perfusion Imaging (LDPI) system (PeriScan PIM II, Perimed 
Instruments, Ardmore, PA) prior to performing surgery, and 1 week intervals after surgery for 4 or 5 
weeks. C57BL6/J mice were used to test the gel delivery system alone (n = 5), while SCID mice were 
used for experiments with human cells (n = 7) to eliminate the adaptive immune reaction by T and B cells 
in response to human-mouse HLA incompatibilities, although natural killer cells are still present
26
. One 
day after surgery, OECs or CACs in culture were stained for 10 minutes with 3ul of Vybrant™ DiD dye 
per million cells (Molecular Probes #V-22887), and were delivered to the blood stream of SCID mice 
using an intracardiac injection to prevent first pass accumulation in the lungs. Mice were humanely 
sacrificed by CO2 inhalation at the end of experiments. Muscles surrounding the vessel ligation site, 
including the semimembranosus, semitendinosus, gracilis and adductor muscles, in the ischemic limb, 
and the same muscle in the contralateral limb were collected and zinc formalin fixed (Anatech Ltd #170) 
for 24 hours. Muscles were then transferred to a 70% ethanol solution prior to paraffin embedding and 
sectioning.  
Immunohistochemical Analysis 
Paraffin embedding and sectioning was performed by the Dana Farber / Harvard Cancer Center 
Histopathology Core (P30 CA06516). 5µm thick paraffin sections, cut perpendicular to muscle fiber 
direction were analyzed for blood vessel density as described previously
12,14,21,27,28
. Briefly, slides were 
soaked in xylene to remove excess paraffin and then rehydrated in decreasing ethanol solutions (100%-
95%-70%), followed by a 30 minute Citrate Buffer (10mM Tri-sodium citrate, pH = 6) epitope retrieval 
step (20 minutes boiling, 10 minutes at room temperature). After washing in Tris Buffer (0.15M Tris-
HCl, 0.1M NaCl, 0.05% Tween 20, pH = 7.6) and applying Blocking Buffer (10% Normal Goat Serum, 
1% BSA in Tris Buffer), rat anti-mouse CD31 antibody (BD # 557355) was applied overnight at 4
o
C for 
the detection of endothelial cells. Slides were then washed again, and an AlexaFluor-568 goat anti-rat 
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secondary (Life Technologies #A-11077) was applied for 1 hour at room temperature. Following a final 
wash, slides were mounted with ProLong gold Anti-fade Reagent with Dapi (Life Technologies #P36935) 
and protected from light until imaged. Muscle sections were imaged on a Zeiss Axio Observer (Zeiss, 
Thornwood, NY) equipped with a Hamamatsu Orca-Flash 4.0 sCMOS camera (Hamamatsu Photonics, 
Bridgewater, NJ). Blood vessel density was quantified from 6 images per mouse (taken from 4 sections 
per animal), 4 mice per condition.   
Statistical Analysis 
Data was compared using a Students unpaired t-test (two-tailed), with a p-value less than 0.05 considered 
significant.           
 
3.4  Results 
OEC and CAC Sprouting Potential  
OECs or CACs were mixed with 100µm collagen coated beads in a spinning flask, alternating between 
static and spinning states over 4 hours, sufficient time to allow cell seeding
13,14
. OECs readily adhered to 
the beads, and proliferated on the beads until forming a confluent layer of cells (Figure 3.1A-B), similar 
to previously reported bead coating by HMVECs and HUVECs
9,13,14
. In contrast, CACs adhered poorly to 
beads.  A few beads were found with one or two CACs adhered, but the majority of beads were empty 
with individual cells still floating in suspension (Figure 3.1C-D). CACs were not used further in sprouting 
assays, because the beads never became confluent with cells. Sprouting assays were initiated with OEC-
covered beads by suspending the beads in a 3D fibrin matrix. OECs then migrated from the beads and 
formed sprouts, mimicking the initial stages of angiogenesis (Figure 3.1E-F). 
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Figure 3.1. Phase contrast images of OECs and CACs after cell seeding procedure on 200µm diameter, collagen-
coated dextran beads and OEC sprout examples. A-B) OECs adhered to beads and proliferated until confluent. Scale 
bars are 500µm (A) and 100µm (B). C-D) CACs did not adhere or proliferate on beads. Scale bars are 500µm (C) 
and 100µm (D).  E-F) Sprouts formed by OECs after seeding in fibrin gel. One sprout (E) and multiple sprouts (F). 
Scale bars are 100µm. 
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Effects of VEGF and SDF on Endothelial Sprouting 
Sprouting assays were used to compare the potential angiogenic ability of OECs, HUVECs and 
HMVECs, and to determine the effects of VEGF and SDF on this ability. Beads coated with OECs, 
HUVECs and HMVECs were placed within a fibrin gel matrix, and VEGF (50ng/ml), SDF (100ng/ml) or 
the combination was added to the media on top of the fibrin gel for 3 days. SDF did not support sprout 
formation by any cell type, whereas VEGF, a known angiogenic cytokine, induced sprout formation by all 
three cell types (Figure 3.2A-C). Surprisingly, the combination of VEGF and SDF promoted the most 
sprout formation by all three cell types. In addition to the positive effect of a constant presence of SDF 
with VEGF, the temporal presentation of SDF may be important for sprouting. This effect is observed 
with VEGF alone, where a decreasing concentration of VEGF over time is known to stimulate the best 
sprout formation by HMVECs
14
. The effect of increasing, decreasing or stable profiles of SDF, overlaid 
on a decreasing profile of VEGF was tested at the day 3 time point (Suppl Figure 3.1A). All profiles of 
SDF supported more sprout formation by OECs, HUVECS, and HMVECs compared to VEGF alone, 
except for a decreasing SDF profile with HMVECs (Suppl Figure 3.1B-D). These data suggest that SDF 
must be present and also maintained at a sufficient level after initial sprout formation in order to have an 
overall effect.  
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Figure 3.2. Endothelial sprouting behavior in response to SDF, VEGF and the combination at 72 hours. A) Images 
of OEC sprouts formed after exposure to control media, or media supplemented with 100ng/ml SDF, 50ng/ml 
VEGF, or the combination. Arrowheads indicate sprouts. Scale bars are 100µm. B-D) Quantification of the number 
of sprouts per bead formed by OECs (B), HUVECs (C), and HMVECs (D). Mean ± SD, n=4. * p < 0.05 compared 
to control condition, 
ǂ
 p < 0.05 compared to VEGF condition. 
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The positive effect of VEGF and SDF on endothelial sprouting may be achieved by promoting faster and 
more continuous sprout formation, or by maintaining sprouts longer. To understand if the combination of 
VEGF and SDF had an effect on the kinetics of initial sprout formation, time lapse microscopy was used 
to image OECs in this sprouting assay. The time at which the first cell protruded from the bead was 
recorded as the sprout initiation time. The SDF alone condition was not tested here since it did not lead to 
an increase in sprouting over the control in the earlier study (Figure 3.2). Both VEGF and VEGF+SDF 
conditions showed faster sprout initiation times relative to the control, with VEGF alone reducing the 
initiation time by one hour, and combining SDF with VEGF further reduced this time by an additional 50 
minutes (Figure 3.3A-B). The total effect of reduced initiation time on sprouting could be observed by 8 
hours, where both conditions with VEGF already showed significantly more sprouts per bead relative to 
the control (Figure 3.3C). To investigate sprout maintenance over time, the number of sprouts per bead 
was compared at 24, 48 and 72 hour time points (Figure 3.4A-C). At 24 hours, more sprouts formed when 
VEGF was present, compared to control and SDF alone, a possible continued effect of reduced sprout 
initiation time. OECs also demonstrated the highest sensitivity to VEGF in the first 24 hours as measured 
by the number of sprouts formed relative to the control (OECs – 5:1, HMVECs – 3:1, HUVECs – 2.2:1). 
While VEGF and VEGF+SDF conditions displayed similar levels of sprouting at 24 and 48 hours, by 72 
hours, the number of sprouts per bead in the VEGF condition dropped significantly for HUVECs and 
HMVECs, and dropped only slightly for OECs. In comparison, the number of sprouts in the condition 
with VEGF and SDF barely decreased for HUVECs and HMVECs, and instead slightly increased for 
OECs. Even though all three cell types exhibited significant differences between the VEGF+SDF and 
VEGF alone conditions at 72 hours, OECs showed the most robust response to VEGF+SDF between 48 
and 72 hours in terms of sprout maintenance. Together, these data demonstrate that the combination of 
VEGF and SDF potently promotes sprouting by all three cells types, possibly by multiple mechanisms, 
including a reduced sprout initiation time, enhanced maintenance of sprouts that have formed and/or by 
encouraging continuous sprouting over time.  
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Figure 3.3. Kinetics of initial OEC sprout formation. A) Histograms of sprout initiation time for OECs with control 
media, or media supplemented with VEGF or VEGF+SDF. B) Population mean and median sprout initiation times. 
Mean ± SEM, Control (n=45), VEGF (n=49), VEGF+SDF (n=44). C) Quantification of the number of sprouts per 
bead formed after 8 hours. Mean ± SD, n=4. * p < 0.05. 
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Figure 3.4. Effect of VEGF and SDF on sprouting at 24, 48, and 72 hours. A-C) Quantification of the number of 
sprouts formed by OECs (A), HUVECs (B) and HMVECs (C). Mean ± SD, n=4. * p < 0.05 compared to all other 
conditions. 
 
We next directly compared the sprouting potential of OECs and mature endothelial cells by seeding either 
OECs and HMVECs or OECs and HUVECs onto the beads together (Figure 3.5A). When OECs and 
HMVECs were cultured together, the combination of VEGF and SDF still promoted more sprouting than 
VEGF alone (Figure 3.5B). OECs typically took the tip cell position in sprouts, and even sprouts which 
had a HMVEC as the tip cell were often supported at the stalk by an OEC; many sprouts were completely 
formed by OECs (Figure 3.5C-D). The percentage of sprouts with OECs vs. HMVECs as the tip cell was 
subsequently quantified. Even though only 38% of the cells initially on the beads were OECs, as 
determined by flow cytometry prior to placing beads in fibrin gels, at 24, 48 and 72 hours 60-70% percent 
of the sprouts had an OEC as the tip cell in both the VEGF and VEGF+SDF conditions (Figure 3.5E). 
Similar trends were revealed when OECs and HUVECs were seeded on the beads together. At 72 hours, 
the combination of VEGF and SDF promoted the most sprout formation, followed by VEGF alone, while 
control and SDF alone conditions showed significantly fewer sprouts (Figure 3.5F). Prior to placing beads 
in the fibrin matrix, 45% of the cells on the beads were OECs. After 72 hours, OECs were found in the tip 
cell location in approximately 60% of the sprouts in the VEGF and VEGF+SDF conditions (Figure 3.5G). 
Direct comparison of OECs to mature endothelial cell types in these assays demonstrates the greater 
sprouting potential of OECs. 
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Figure 3.5. Direct comparison of OEC sprouting with HUVECs and HMVECs. A) Phase contrast image of OECs 
and HMVECs seeded onto 200µm beads, with image of fluorescently labeled OECs overlaid. B)  Quantification of 
total sprouts per bead formed by OECs and HMVECs at 24, 48 and 72 hours. Mean ± SD, n = 4. * p < 0.05 
compared to all other conditions. C) Sprout formed by a HMVEC and supported by an OEC at the base. D) Sprout 
formed by OECs. E) Percentage of sprouts with an OEC as the tip cell when seeded with HMVECs. Red line 
indicates initial percentage of cells that were OECs. F) Total number of sprouts per bead formed by OECs and 
HUVECs at 72 hours. Mean ± SD, n = 4. * p < 0.05 compared to control condition, 
ǂ
 p < 0.05 compared to VEGF 
condition. G) Percentage of sprouts with an OEC as the tip cell when seeded with HUVECs. Red line indicates 
initial percentage of cells that were OECs. 
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Paracrine Support of Angiogenesis by OECs and CACs 
In addition to OECs directly participating in angiogenesis, secreted factors from OECs and CACs may 
contribute to new blood vessel formation in a paracrine fashion. To test this possibility, OECs and CACs 
were seeded on top of fibrin gels which contained HUVEC-coated beads; both VEGF and control 
conditions were tested.  The number of sprouts per bead was counted after three days. Again, VEGF 
increased sprouting compared to the control when no progenitors were seeded on top of the gel. In both 
VEGF and control conditions, the presence of OECs increased sprouting by 35%, while CAC presence 
doubled the number of sprouts formed (Figure 3.6A). To determine if OECs and CACs secreted 
angiogenic factors, an ELISA-based array for angiogenic cytokines was used to analyze conditioned 
medium from both cell types. Both OECs and CACs were found to secrete TIMP-2, IL-8, VEGF, FGFb 
and IL-12. OECs also secreted PlGF, IL-6, TNFα, and FGFa, while CACs secreted leptin (Figure 3.6B; 
Suppl Figure 3.2A). The level of these secreted cytokines, collected from three independent experiments 
for each cell type, was also quantitatively measured using standard ELISA plates. The relative levels of 
cytokines secreted from OECs and CACs demonstrated the same trend as was measured with the 
angiogenesis array (Figure 3.6C). Both cell types secreted VEGF, FGFb, IL-12 and IL-8; here, CACs 
secreted more IL-8 than OECs. Only OECs secreted PlGF and only CACs secreted leptin. When OECs 
and CACs were exposed to VEGF and SDF, the angiogenesis array suggested that relative amount of 
many secreted cytokines increased, including PlGF, IL-8, IL-6, FGFb and FGFa from OECs and IL-8, 
FGFb, IL-12, and leptin from CACs (Suppl Figure 3.2A-B). ELISA analysis confirmed a slight increase 
in IL-8 secretion from OECs, and an increase in FGFb, IL-12 and leptin from CACs, while the other 
measured factors remained unchanged (Suppl Figure 3.2C). A number of these factors are known to have 
angiogenic activity, and their secretion by OECs or CACs could enhance new blood vessel formation by 
host endothelial cells. In order to determine the relative potency of these factors, PlGF, IL-8, FGFb, 
Leptin, and VEGF as a positive control, each at 10ng/ml, were added to fibrin gels containing HUVEC-
coated beads. At this concentration, FGFb, Il-8 and VEGF significantly increased sprouting by HUVECs, 
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while PlGF and Leptin showed only modest effects (Figure 3.6D). Further, blocking antibodies were 
applied to neutralize the positive effect of each of these factors when secreted from OECs or CACs 
(Figure 3.6E). Blocking PlGF, FGFb, IL-8, or all three in combination significantly reduced HUVEC 
sprouting when OECs were placed on top of the fibrin. Similarly, blocking IL-8, FGFb, Leptin or the 
combination also significantly reduced HUVEC sprouting when CACs were on top of the fibrin.  
 
 
Figure 3.6. Paracrine effects of factors secreted by OECs and CACs. A) The number of sprouts per bead formed by 
HUVECs when 50,000 OECs or CACs were placed on top of the fibrin gel for 3 days. Potency of secreted factors 
from OECs and CACs are shown in comparison to the enhanced sprouting potential achieved with VEGF+SDF 
media. Regular media is EBM-2+5%FBS, VEGF media has 50ng/ml VEGF added to regular media. SDF was used 
as normal at 100ng/ml. Mean ± SD, n = 4. * p < 0.05 compared to regular media with no cells, 
ǂ
 p < 0.05 compared 
to VEGF media with no cells. B) Secretion of angiogenic factors from OECs and CACs as measured on an ELISA-
based array. Adjusted for cell number, and plotted relative to positive control condition on the array (See 
Supplemental Figure 2). C) ELISA detection of factors secreted from OECs and CACs. Adjusted for cell number. 
Mean ± SD, n = 3. 
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Figure 3.6 (Continued)
 
 
Figure 3.6 (Continued). D) Relative increase in HUVEC sprouting over the control with the addition of various 
angiogenic factors each at 10ng/ml. Mean ± SD, n = 4. E) Relative reduction in sprouting with the application of 
blocking antibodies for factors secreted by OECs or CACs. The combination condition (All) indicates blocking of 
PlGF, IL-8 and FGFb for OECs and IL-8, FGFb, and Leptin for CACs. Mean ± SD, n = 4. * p < 0.05. 
 
These in vitro data together confirmed that OECs can directly participate in sprout formation, while CACs 
do not. On the other hand, CACs more potently promoted endothelial cell sprouting in vitro, on a per cell 
basis compared to OECs, likely due to secretion of factors that acted in a paracrine manor. Exposure to 
VEGF and SDF increased OEC sprout formation, and also slightly increased secretion of angiogenic 
factors from both cell types, which could potentially influence their contributions to new blood vessel 
growth. 
In Vivo Effects of VEGF and SDF Delivery 
As I am proposing to utilize VEGF and SDF delivery to enhance the localization and function of 
transplanted OECs and CACs, it will be important to understand the role of these factors when used alone 
to treat ischemic tissues. Sustained local delivery of VEGF from polymer scaffolds has previously been 
shown to promote angiogenesis and restore perfusion in a mouse model of hind-limb ischemia
13,14,21,23
. I 
have found that VEGF and SDF together potently promote angiogenic sprouting in vitro, therefore the 
ability of these cytokines to support angiogenesis was tested in the same hind-limb ischemia model used 
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for VEGF studies. Alginate gels that released VEGF and SDF, VEGF alone, or control gels (See Chapter 
2, Figure 2.5 for release profiles) were injected into the hind-limb muscle tissue of C57Bl/6J mice 
immediately after ischemia was induced. Laser Doppler Perfusion Imaging (LDPI) was used to monitor 
blood perfusion in the ischemic limb relative to the control limb at one week intervals following surgery. 
Both VEGF and VEGF+SDF gel treatments performed significantly better than control gels, restoring 
blood flow to a higher level at 5 weeks (Figure 3.7A). Gels delivering a combination of VEGF and SDF 
did not improve perfusion recovery better than VEGF-only gels, perhaps because the VEGF-only gels 
were highly effective in this animal model of ischemia.  
OEC and CAC Recruitment for Ischemic Reperfusion 
Since both types of endothelial progenitors were found to contribute to angiogenic sprouting in vitro, both 
directly (OECs) and via paracrine signaling (OECs and CACs), the ability of these cells to enhance 
angiogenesis and restore perfusion was next tested in vivo in the mouse hind-limb ischemia model. OECs 
or CACs were systemically delivered via intracardiac injection into SCID mice one day after mice had 
undergone hind-limb ischemia surgery. Mice also received a local injection of a control alginate gel or 
alginate gel containing VEGF and SDF in the muscle surrounding the site of vessel ligation, to 
additionally assist with progenitor cell accumulation in the nearby tissue. Mice that received only a 
control alginate gel injection showed poor overall recovery, with the blood flow ratio in the ischemic limb 
versus the contralateral, non-ischemic limb only reaching 48% four weeks after surgery (Figure 3.7B). At 
the same time point, there was a trend of increased perfusion for mice which had received VEGF+SDF 
gels or VEGF+SDF gels with an injection of OECs (55% blood flow ratio), compared to the control, but 
these differences were not statistically significant. Strikingly, though, transplantation of CACs into mice 
which had received VEGF+SDF gel injection led to a significantly improved blood flow ratio by four 
weeks compared to all other conditions. These mice showed perfusion recovery in the ischemic limb that 
reached 73% of the level in the contralateral, control limb. Blood vessel density in the hind-limbs was 
quantified by staining tissue sections for CD31, an endothelial cell marker, to confirm that perfusion 
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differences were due to vessel formation or maintenance. Here, all treatment conditions showed 
statistically significant differences compared to control gels, and VEGF+SDF gels with a CAC injection 
also demonstrated significantly higher blood vessel density compared to VEGF+SDF gels alone or gels 
with an OEC injection (Figure 3.7 C-H). These in vivo data show that systemic delivery of CACs leads to 
improved perfusion recovery and increased blood vessel density, while delivery of OECs does not 
enhance recovery or capillary density over VEGF+SDF gels alone. 
 
Figure 3.7. Blood vessel perfusion recovery and capillary density after hind-limb ischemia surgery with VEGF and 
SDF treatment, with and without OEC or CAC delivery.  A) C57BL6/J mice were treated with injectable alginate 
gels loaded with VEGF or VEGF+SDF, or control gels. Perfusion is plotted as the ratio of the mean perfusion in the 
ischemic limb over the non-ischemic, contralateral limb. Mean ± SD, n = 5. * p < 0.05 for VEGF and VEGF+SDF 
compared to the control. B) Blood perfusion ratio in ischemic hind-limbs of SCID mice after treatment with 
VEGF+SDF gels and a systemic injection of either OECs or CACs, compared to control alginate gels with no cell 
delivery. Mean ± SD, n = 7. * p < 0.05. 
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Figure 3.7 (Continued)
 
Figure 3.7 (Continued). C-G) Images of hind-limb muscle sections stained with CD31 from control (C), 
VEGF+SDF gel only (D), VEGF+SDF gel  with OEC delivery (E), VEGF+SDF gel with CAC delivery (F) 
treatment conditions, and a healthy, non-ischemic limb (G). Scale bars are 100µm. H) Quantification of blood vessel 
density in ischemic hind-limbs 4 weeks after surgery. Mean ± SD, n = 4 mice per condition. ** p < 0.01.  
 
3.5  Discussion 
The results of these experiments together clarified the roles of OECs and CACs in contributing to sprout 
formation, and revealed the effects of VEGF and SDF on each cell types’ role. Specifically, OECs formed 
sprouts, while CACs did not, in this 3D model of angiogenesis. In direct comparison to mature 
endothelial cells, OECs preferentially localized to the tip cell position. The combination of VEGF+SDF 
yielded more sprouts per bead for OECs, HUVECs, and HMVECs compared to either factor alone or 
control media. The combination of VEGF+SDF also reduced OEC sprout initiation time, resulted in the 
most sprout formation relative to the control at 24 hours, and showed better sprout maintenance at 72 
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hours compared to HUVECs and HMVECs.  OECs and CACs both supported sprout formation by 
HUVECs in a paracrine manner; on a per cell basis, the cytokines from CACs were more potent than 
those from OECs. Blocking factors secreted by OECs and CACs, including PlGF, IL-8, FGFb, and 
Leptin, significantly reduced sprouting by HUVECs. Finally, testing the functional contribution of both 
endothelial progenitor cell types showed that CACs, which accumulated in the ischemic hind-limb with 
local delivery of VEGF and SDF from an alginate hydrogel, promoted perfusion recovery better than 
accumulated OECs or gels alone. 
Comparisons of endothelial progenitors with mature endothelial cells showed that OECs formed sprouts, 
similar to HUVECs and HMVECs, while CACs did not in this assay. CACs did not adhere to the beads 
used in the sprouting assay, and therefore could not form sprouts. Previous studies have used a 2D tube-
forming assay to assess angiogenic capabilities, which have indicated that ‘early-EPCs’ (CACs) can 
participate in tube formation when co-incubated with HUVECs, but not alone
29,30
. Tube-forming assays 
also yield false positives, as CD34+ cells can form tubes, even though these are a mixture of cells of 
hematopoietic lineage, which do not form vessels in vivo
19,31,32
.  The 3D sprouting assay was also used to 
directly compare the ability of OECs vs. HUVECs or HMVECs to form sprouts by co-seeding both cell 
types onto beads, and allowing them to compete for tip cell position. OECs were preferentially found in 
the tip cell location compared to HMVECs, and often also supported sprouts initiated by HMVECs at the 
stalk. Additionally, the profile of the number of sprouts per bead at 24, 48, and 72 hours resembles that of 
OECs alone more than HMVECs alone. The ratio of OECs to HMVECs on the beads was counted at the 
start of the experiment, but this was not quantified each day. Preferential sprout formation by OECs could 
also be achieved by their higher proliferation rate over HMVECs, but this would also lead to an 
increasing fraction of OEC sprouts over time, which was not observed. When OECs were directly 
compared to HUVECs, similar trends were observed, with OECs preferentially localizing to the tip cell 
position. These experiments demonstrated that OECs have an increased capability to form sprouts, and 
also function in concert with mature endothelial cells. These results are further in agreement with other 
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models of vessel network formation, in which evenly distributed OECs in a 3D collagen gel matrix 
condense to form vessel-like structures which have increased microvessel density compared to networks 
of HMVECs
33
.  Therapeutically, this suggests that if OECs are correctly located at sites of new blood 
vessel growth, they should exhibit a higher angiogenic potential than the resident endothelial cells, but 
this in vivo result was not shown here.  
The combination of VEGF and SDF had a significant effect on sprouting OECs and endothelial cells. 
First, VEGF and SDF together increased sprouting at 72 hours for OECs, HUVECs and HMVECs 
compared to VEGF alone, SDF alone or control media. VEGF is known to promote blood vessel 
formation in vitro and in vivo, and has been tested in this assay previously
13,14
. SDF on the other hand is 
claimed to be angiogenic because it supports tube formation in 2D assays, although again, this is not a 
rigorous assay
16
. Here, SDF alone did not stimulate sprout formation at any time point, while the 
combination of VEGF and SDF synergistically promoted sprouting. Previous studies have shown that 
mature endothelial cells exposed to SDF, secrete VEGF, and cells exposed to VEGF secrete SDF as well 
as up-regulate the expression of CXCR4 (the receptor for SDF), possibly protecting the cells from 
desensitization
16,34
. These interactions have the potential to create an autocrine positive feedback loop, 
and may be responsible for strong sprout promotion. The resultant increased sprouting can be 
accomplished by reducing the sprout initiation time, encouraging more continuous sprout formation, 
and/or by maintaining sprouts for longer. The combination of VEGF and SDF was shown to reduce the 
sprout initiation time. At later time points, the significant differences between VEGF+SDF and other 
conditions could be achieved by either of the other two mechanisms. In the experiments performed here, 
the initiation time of only the first sprout formed was recorded, but the initiation time, total time of sprout 
maintenance, and retraction time for all sprouts between 0-72 hours was not determined. VEGF and SDF 
were shown to promote OEC migration chemotactically (Chapter 2, Figure 2.4), but this combination 
could perhaps also increase migration of OECs in a chemokinetic manner. SDF has been shown to induce 
actin polymerization through a RhoA- ROCK1 dependent pathway, which results in increased migration 
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in multiple myeloma cells
35
. Here, VEGF and SDF may act synergistically to enhance the overall 
migratory ability of OECs, which could help promote continuous sprout formation by individual cells, 
since sprouting is initiated by migration of a cell into the fibrin matrix. Enhancing OEC migration with 
the combination of VEGF and SDF could then be responsible for the increase in total number of sprouts 
formed, even if the retraction rate is similar in all conditions. Analysis of the full dynamics would reveal 
which mechanism is responsible for a higher number of sprouts per bead at later time points. Overall, 
these experiments suggest that the combination of VEGF and SDF has a strong potential to support new 
blood vessel formation, both by resident mature endothelial cells and by OECs that have localized to 
ischemic tissue. 
OECs and CACs were also shown to stimulate HUVEC sprout formation by secreting angiogenic factors 
that act in a paracrine manner. While both progenitor cell types secrete multiple factors, the combination 
of factors secreted by CACs was more potent than from OECs.  Both cell types secreted IL-8, VEGF and 
FGFb, which are known to be angiogenic
8,36
 and was also demonstrated here, while only OECs secrete 
PlGF and CACs secrete leptin. The addition of blocking antibodies to each of these factors reduced 
sprouting by HUVECs significantly, demonstrating the importance of each component. Mature 
endothelial cells also secrete IL-8 and FGFb
12
, which likely was responsible for the dramatic decreases in 
sprouting when each of these factors was blocked. An alternative method to eliminate the contribution of 
secreted factors from OECs and CACs, while keeping HUVEC signaling intact, would be to use siRNA 
against IL-8 and FGFb. This would allow the determination of the relative importance of each factor, and 
may elucidate whether the difference in IL-8 secretion is mainly responsible for the increased potency of 
CACs compared to OECs. Furthermore, the angiogenesis array assays for many common factors involved 
in new blood vessel formation, but there are still other factors and combinations that may support 
angiogenesis and be secreted by progenitors which were not tested here, including SDF, Insulin-like 
Growth Factor, Epidermal Growth Factor, etc. Of the cytokines investigated, these experiments confirmed 
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that factors secreted by OECs and CACs support angiogenesis by directly modifying endothelial 
sprouting potential. 
In vivo functional testing of blood perfusion recovery showed that CACs, which were recruited to the 
ischemic hind-limb and exposed to VEGF+SDF from an alginate hydrogel, performed better than OECs 
gels alone.  First, the baseline recovery for VEGF+SDF gels was established, since this combination of 
factors showed significantly enhanced sprout formation in vitro. In C57BL6/J mice, VEGF+SDF gels out-
performed control gels, but not VEGF-only gels, possibly due to the fact that VEGF treatment alone 
showed pronounced perfusion recovery in this animal model. SDF-only gels were not tested in this model 
because SDF did not promote sprout formation in the in vitro model system, and in vitro sprouting assay 
results often correlate with perfusion recovery performance in vivo
10,13,14
. VEGF is produced naturally in 
response to ischemia
8
, therefore it may be possible for the exogenously delivered SDF to interact with the 
endogenous VEGF to promote enhanced recovery. In SCID mice, the effect of VEGF+SDF gel treatment 
over the control is markedly reduced, likely due to the severity of the ischemic injury. VEGF+SDF gel 
treatment resulted in a higher capillary density, but this did not translate to a statistically significant 
difference in perfusion. This result is not unexpected for SCID mice, as VEGF-only treatments also have 
not been shown to promote significant perfusion differences, whereas endothelial progenitor cell and 
growth factor combination treatments are more effective
12
.  
As modeled in the sprouting assays, CACs secrete factors that act in a paracrine manner to potently 
promote angiogenesis, which may be the mechanism by which enhanced functional perfusion recovery is 
achieved. The panel of factors secreted by CACs promoted sprout formation more strongly than those 
from OECs, and additionally, CACs were shown (in Chapter 2) to accumulate more efficiently than 
OECs. The combination of secreting more potent angiogenic factors and accumulating in greater number 
could both explain why CACs demonstrated a significant therapeutic effect compared to OECs. Further, 
while these factors were shown to directly act on endothelial cells, they may also enhance or alter the 
recruitment of other cell types to the ischemic limb as well as influence their behavior or the behavior of 
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other support cells. In Chapter 2, CAC accumulation in non-ischemic limbs led to a significant and 
multiplicative effect on the infiltration of inflammatory cells, including CD11b+ cells (myeloid-lineage), 
F4/80+ cells (macrophages) and Gr1+cells (likely granulocytes), but this was not tested in ischemic limbs. 
If VEGF+SDF delivery and CAC localization in ischemic limbs alter the presence of inflammatory cell 
populations (e.g. macrophages, see Chapter 2, Figure 2.6 and 2.9), these cells could also potentially 
contribute to neovascularization in a paracrine manner or by physically interacting with endothelial 
cells
37
. Alternatively, it is unknown how long the CACs maintain a presence or stay alive in the ischemic 
limb, and for how long they secrete significant levels of cytokines. The exact location of CACs is also 
unclear, but (as shown in Chapter 2) some are likely stuck in capillaries, a reasonable proximity to act on 
resident endothelial cells. Lastly, it is unknown whether CACs can promote the same level of perfusion 
recovery if allowed to accumulate due to ischemia alone, without a VEGF+SDF-releasing alginate gel. 
Overall though, CACs were effective at restoring blood flow to the ischemic limb.  
OECs were also shown to preferentially accumulate in ischemic limbs, but their presence was not 
therapeutically beneficial. OECs demonstrated potential to contribute to blood vessel formation in vitro 
by directly participating in sprouting and by secreting paracrine factors, which were both promising 
results before moving in vivo. Similar to many cell therapies, it is likely that too few OECs were recruited 
to observe enhanced recovery (Chapter 2, Figure 2.9)
38
; they may also not be in the correct location or 
microenvironment to participate. These issues can potentially be overcome by using biomaterials for cell 
delivery. Biomaterial systems have been designed with specific microenvironments that maintain cell 
viability and promote cell deployment into surrounding tissue
12
. Alginate hydrogels loaded with VEGF121 
enhanced migration of OECs from the scaffold, which were later found within blood vessels
12,39
. 
Additionally, tissue engineered networks of blood vessels that have been pre-formed within a biomaterial 
can anastomose with host vessels to carry blood and perfuse tissue
33,40–42
. Since the combination of VEGF 
and SDF increased sprout formation significantly in the in vitro models tested here, it may also possibly 
enhance or speed the formation of these ex vivo engineered vessel networks. Even though OECs were not 
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effective in vivo with the delivery method employed here, biomaterial-based solutions exist which achieve 
a therapeutic benefit, supporting the future use of these cells. In summary, the results of these experiments 
emphasize the enhanced regenerative capacity of endothelial progenitors and validate the use of these 
cells in therapies for the treatment of ischemia as contrasted to relying on resident endothelial cells alone. 
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CHAPTER 4:  
Major Conclusions, Implications and Future Directions 
 
4.1  Major Conclusions 
Endothelial progenitors have shown therapeutic potential as a treatment for ischemic cardiovascular 
diseases, but with limited efficacy likely because too few cells reach the tissue of interest
1,2
. A biomaterial 
system was used here to create a tissue microenvironment capable of enhancing the recruitment of 
endothelial progenitors and encouraging their contribution to neovascularization. Specifically, SDF and 
VEGF, two factors that play key roles in modulating progenitor cell trafficking
3
, were delivered from 
alginate hydrogels and were tested for therapeutic efficacy. This biomaterial system was used to 
investigate the hypothesis that local, sustained delivery of exogenous VEGF and SDF can enhance 
recruitment of endothelial progenitors to ischemic sites and also promote their contribution to new blood 
vessel growth. In addition, all studies were performed with both OECs and CACs in order to compare the 
specific roles and therapeutic potential of these two cell populations. 
The first aim of this thesis focused on the mechanism by which cells are recruited to target tissues. In 
vitro assays were used to dissect the influence of VEGF and SDF on both adhesion and migration, two 
key steps in the homing process. SDF increased adhesion of both OECs and CACs to endothelial cells in 
static and flow-based assays. CACs were more responsive than OECs to changes in the inflammatory 
state of endothelial cells and to SDF exposure, likely due to higher β2 expression. In contrast to SDF, 
VEGF is not implicated in the modulation of adhesion. SDF enhanced migration of CACs, while the 
combination of VEGF and SDF increased migration of OECs to a greater extent than either factor alone. 
The ability of VEGF and SDF to enhance adhesion and migration of OECs and CACs in vitro suggested 
that these factors may have a substantial impact on recruitment in vivo.  VEGF and SDF released from 
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alginate hydrogels in target tissues significantly increased recruitment of OECs and CACs in vivo both in 
ischemic and non-ischemic muscle tissue.  In close agreement with in vitro trends, CACs accumulated to 
a greater extent than OECs. VEGF and SDF delivery exhibited a minimal impact on inflammatory cell 
infiltration, affecting only macrophages, but not the other cell types tested. Interestingly, systemic 
injection of CACs led to significant infiltration of inflammatory cells at the gel injection site in non-
ischemic mouse hind-limbs. Overall, the work presented in Aim 1 established that VEGF and SDF release 
from alginate hydrogels constitutes an effective strategy to increase endothelial progenitor recruitment to 
target tissues, and that CACs are recruited more efficiently than OECs. 
The second aim of this thesis concentrated on the roles of OECs and CACs in contributing to new blood 
vessel growth and the effects of VEGF and SDF on each cell types’ role. In a three-dimensional in vitro 
sprouting model, OECs directly participated in sprout formation, while CACs could not. In addition, 
OECs demonstrated a greater potential to initiate sprouts when placed directly in competition with mature 
endothelial cells. The combination of VEGF and SDF dramatically increased sprouting by OECs, likely 
by reducing sprout initiation time and improving sprout maintenance.  OECs and CACs enhanced sprout 
formation by mature endothelial cells through secretion of angiogenic factors that acted in a paracrine 
manner. On a per cell basis, factors secreted by CACs were more potent than those from OECs. These in 
vitro assays confirmed that OECs and CACs play different roles in contributing to the formation of new 
blood vessels. Finally, homing of CACs to ischemic limbs containing VEGF and SDF alginate gels 
improved perfusion recovery better than accumulated OECs or gels alone in an in vivo mouse model. The 
results presented in Aim 2 clearly demonstrated that OECs can take part in angiogenic sprout formation, 
and this process was significantly enhanced by VEGF and SDF.  In contrast, CACs were limited to 
secreting paracrine factors that encourage sprout formation by endothelial cells.  In vivo, CACs were 
more therapeutically effective than OECs in these studies.  
The results of the experiments performed in this thesis comprehensively show that local delivery of 
exogenous VEGF and SDF from an alginate hydrogel enhanced recruitment of endothelial progenitors to 
106 
 
ischemic tissue, which allowed significant contribution to perfusion recovery by CACs. VEGF and SDF 
promoted sprout formation by OECs in vitro, but systemically delivered OECs that accumulated in the 
ischemic tissue did not improve overall blood perfusion.  
 
4.2  Implications and Future Directions 
The results of these studies emphasize the differing roles of OECs and CACs, and suggest that their use 
therapeutically should differ as well. These findings may also guide the investigation of new methods to 
enhance recruitment of circulating cells for improving cell therapy outcomes in general, as well as the 
development of strategies to augment endothelial progenitor contribution to neovascularization.  
Circulating Angiogenic Cells 
CACs were highly responsive to SDF, as demonstrated by enhanced recruitment in vivo, and were 
therapeutically effective at restoring blood perfusion to ischemic tissue. Together, these results emphasize 
the clinical potential of using CACs as a traditional, systemically delivered cell therapy in combination 
with a biomaterial system designed to increase their targeting efficiency. These results also establish SDF 
as a promising candidate for delivery from a biomaterial system clinically, particularly considering SDF’s 
well-recognized role in cell trafficking
3
. 
Important questions still remain, related to the precise mechanism by which controlled release of VEGF 
and SDF enhanced recruitment of CACs to target tissues and led to improved therapeutic recovery as 
compared to gels alone. Only SDF is implicated in modulating adhesion, and CACs also only showed 
increased migration towards SDF, while VEGF had no effect. Therefore, it is possible that VEGF may not 
have an effect on CAC recruitment in vivo, but SDF-only and VEGF-only gels would need to be studied 
to dissect the roles of each individual factor. If SDF-only gels recruit an equal number of CACs as the 
VEGF+SDF gels, then they may also show similar regenerative capabilities as the combination gels, if 
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recovery is highly dependent on the number of CACs present. Alternatively, the VEGF may be essential 
for inducing sprouting by endogenous endothelial cells and for creating a pro-angiogenic 
microenvironment. A further possibility is that the paracrine factors secreted by a small number of CACs 
are potent enough to exhibit a therapeutic effect, even without SDF to increase their recruitment or VEGF 
to stimulate endothelial cells. 
A major focus of future work should be determining the mechanism by which CACs achieve their 
therapeutic effect. The results presented in Aim 2 made clear that CACs do not directly participate in 
blood vessel growth, but they exhibit two behaviors that both may enhance regeneration. CAC 
localization leads to significant infiltration of various other types of inflammatory cells, which could 
subsequently contribute to vessel growth
4
. CACs also secrete a panel of potent angiogenic factors that can 
act on mature endothelial cells to induce sprout formation. Examining the extent to which of these 
mechanisms is responsible for the improved recovery from ischemia by CACs should be a priority for 
future studies. First, it should be determined if CACs can modulate the infiltration of inflammatory cells 
within ischemic tissue, since a large number of these cells are inherently recruited after induction of 
ischemia. If the presence of CACs alters the profile of recruited cells, then those specific cells could be 
delivered without CACs after inducing ischemia to assess whether that cell population exerts a therapeutic 
effect. Macrophages are one example of possible cells recruited by CACs that may mediate improved 
healing
4
. This could be tested by delivering macrophages directly to the ischemic hind-limb to determine 
if the increased presence of these cells improves blood vessel regeneration. Second, the cytokines and 
growth factors secreted by CACs likely act both on endothelial cells and stimulate inflammatory cell 
recruitment. It is also possible that physical interactions between CACs and other accessory cells are 
essential for therapeutic efficacy. The paracrine and physical effects of the CACs on both perfusion 
recovery and inflammatory cell infiltration could be discriminated by comparing CAC delivery to 
delivery of conditioned media from CACs. Specifically, conditioned media from CACs could be 
collected, concentrated and then delivered into hind-limb muscle, possibly within an alginate hydrogel to 
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provide sustained release, in order to determine if these cytokines alone induce infiltration of 
inflammatory cells (on a short time scale) and/or improve perfusion recovery in an ischemia model (on a 
long time scale). Results from this set of experiments would clarify how the presence of CACs led to a 
beneficial therapeutic effect. 
Independent of the mechanism by which CACs contribute to regeneration, their therapeutic efficacy could 
likely be improved by further increasing the number of CACs within ischemic tissue. One method to 
accomplish this would be to increase the number of CACs in culture that can be re-delivered. The culture 
methods employed to isolate CACs result in a population of cells with almost non-existent proliferation 
potential
5
. As CACs are a type of monocyte
6
, it may be possible to adapt alternative culture methods that 
promote proliferation while maintaining the beneficial properties of CACs. It is likely that some period of 
cell culture is necessary to obtain the CAC population, because injecting freshly isolated CD14+ 
monocytes does not yield a sufficient therapeutic effect
7
. Further, the field as a whole would significantly 
benefit from a better understanding of the general biology of CACs (e.g. determining their origin, their 
relationship to and differentiation from myeloid precursors, and standardized cell markers or a genetic 
profile definition for these cells). This could partially be accomplished through direct comparisons with 
the better understood behaviors of different monocyte populations (e.g. Classical/Inflammatory 
CD14
++
/CD16
-
 monocytes, Non-Classical/Resident/Patrolling CD14
+
/CD16
++
 monocytes, or Intermediate 
CD14
++
/CD16
+
 monocytes)
8–11
. (See Appendix F for CD14 and CD16 co-staining of CACs.) 
Inflammatory monocytes and patrolling monocytes, for example, infiltrate acutely injured ischemic tissue 
with different temporal profiles. Following myocardial infarction, inflammatory monocytes are first 
recruited in high numbers in a CCR2-dependent manner after being released from both the bone marrow 
and spleen
9
. These cells secrete the pro-inflammatory cytokine TNFα. The heart muscle tissue then 
transitions to being populated by the patrolling monocytes, which are recruited in a CX3CR1-dependent 
manner, and exert a pro-angiogenic function by secreting VEGF
9
. Monocytes may also give rise to 
Macrophages and Dendritic Cells that can participate in tissue repair
12,13
. A better understanding of the 
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relationship of CACs to these monocyte populations may reveal that only a specific subset of the CAC 
population exhibits a strong regenerative potential, which could translate to a more efficient therapeutic 
use of these cells.   
A second method to increase the number of CACs in the target tissue could be achieved by further 
enhancing their recruitment or by delivering the cells directly into the tissue, either by bolus injection or 
within a biomaterial system.  Biomaterials may be especially useful because of the beneficial effects of 
delivering cells within a protected and controlled environment. The design of a biomaterial system should 
account for the specific mechanism by which CACs contribute to new vasculature. For example, if 
paracrine secretion of factors is most important, then the cells should be delivered in a material that easily 
allows diffusion of these factors to the surrounding environment. On the other hand, if CACs need to be 
in close proximity or physically interact with sprouting endothelial cells, then the biomaterial should 
encourage deployment of the cells beyond its boundaries
14
. As discussed above, the mechanism of CAC 
contribution to new vessel growth is still unknown.  
Traditional cell therapies that employ systemic delivery eventually may not be needed if it becomes 
possible to recruit endogenous CACs directly out of the circulation. For this reason, a thorough 
understanding of how to enhance targeting and how to selectively recruit subsets of CACs will prove 
valuable for eventual clinical translation. To this end, a careful, quantitative study of the specific 
concentrations and kinds of gradients that effectively induce recruitment may be beneficial for designing 
a more effective material-based therapy. Preliminary studies were initiated using a dual-channel 
microfluidic device that mimics the vascular and extracellular tissue compartments
15
. This device was 
capable of presenting SDF from the extracellular compartment to progenitor cells flowing through the 
vascular compartment (See Appendix C). This device allows investigation of the effects of chemokine 
exposure on both adhesion and migration of endothelial progenitors, thereby creating a physiologically 
relevant model of the complete recruitment process. Hopefully, when an ‘endothelial progenitor cell’ 
(CACs, OECs, or a subset) can be identified from the circulation by surface markers, the information 
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gathered about effective chemokine gradients using these devices could be employed to recruit cells 
directly. 
Outgrowth Endothelial Cells 
In vitro studies demonstrated that OECs exhibit a superior potential to directly contribute to 
neovascularization compared to mature endothelial cells, but they showed minimal recruitment in vivo 
and an overall insignificant therapeutic effect. OECs were likely not deployed in vivo in a manner that 
permitted a therapeutic benefit, since direct delivery of OECs within alginate hydrogels that were 
designed to release the cells within the tissue of interest led to enhanced perfusion
14
. These results suggest 
that OECs are better suited to local delivery methods using biomaterials to control the microenvironment.  
OECs have also been shown to form networks of blood vessels in three-dimensional scaffolds, which 
could be adapted for the treatment of ischemic diseases
16,17
. These ex vivo formed networks anastomose 
with host vessels upon implantation
16,18
. Investigations using these vessel networks are most often focused 
on tissue engineering applications, where blood flow and oxygen delivery are essential to the formation of 
any tissue with a diameter greater than ~200µm (based on the diffusion limit of oxygen)
17,19,20
. (See 
Appendix G for a comparison of OEC and HUVEC network forming potential in a fibrin-PLGA 
scaffold.) The local deployment of a healthy vascular network could possibly alleviate ischemic damage 
due to insufficient blood flow by replacing the dysfunctional vessels. For example, preformed networks of 
vessels made of OECs could be implanted in the muscle tissue in a mouse model of hind-limb ischemia in 
order to determine the therapeutic potential. The normal recovery process includes angiogenic sprouting 
by resident endothelial cells to form a capillary network, which then remodels over time to regenerate 
larger vessels
21
. Implantation of a pre-formed network may allow the healing tissue to effectively skip the 
sprouting phase and directly go to the remodeling phase. Additionally, incorporating VEGF into these 
vascular networks may speed the rate at which the implanted vessels anastomose with host vessels. 
Overall, the recruitment strategies employed in this thesis did not yield beneficial therapeutic outcomes 
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with OECs, but OECs have a great potential to contribute to new vessel formation if they are delivered 
within a proper, supporting microenvironment. 
The effect of VEGF and SDF on OEC sprouting was very dramatic and likely results from decreased 
sprout initiation time and better sprout maintenance, but the molecular mechanisms by which these 
behaviors are achieved remain undefined. It would be interesting to understand the full dynamics (e.g. by 
completing and analyzing 72 hour time lapse experiments) and the molecular mechanisms involved in this 
process (e.g. whether it is caused by maintenance of CXCR4 expression, increased signaling in pathways 
related to migration, or some other mechanism)
22–26
. Further, the combination of VEGF and SDF may 
also prove beneficial to speed the formation or maintain the growth of the aforementioned ex vivo vessel 
networks.  
Finally, the overall low recruitment efficiency in these studies, although enhanced by VEGF and SDF, 
was still less than 1%, which is typical for cell therapies. The low number cells reaching target tissues 
through systemic delivery is an inherent problem and may be an insurmountable challenge to their clinical 
utility.  It is likely that too many cells simply become trapped in capillaries throughout the entire body, 
especially in highly vascularized tissues such as the lungs and liver. The use of biomaterials for cell 
delivery currently may be the best strategy for maintaining viability and controlling localization within 
the tissue of interest, especially since many attractive materials exist and have been validated in pre-
clinical and clinical studies
27
. Studying the recruitment and trafficking is valuable though, because 
incremental improvements could have significant, and possibly multiplicative, therapeutic effects (e.g. for 
each CAC recruited, hundreds of inflammatory cells are recruited (Chapter 2, Figure 2.8) that may 
subsequently enhance healing). It may also be possible that only certain subsets of CACs or OECs are 
sensitive to recruitment signals, and/or that the culture methods employed to isolate these cells alter their 
ability to respond compared to the circulating cell types that give rise to either CACs or OECs. Again, if 
these cell types eventually can be identified based on specific surface marker expression, then they could 
be directly recruited from the circulation without the need for an isolation procedure. 
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In summary, OECs and CACs both demonstrated the capacity to contribute to new blood vessel 
formation, and should be investigated further to determine the best method to deploy these cells in order 
to yield the greatest therapeutic benefit. 
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APPENDIX A: 
Chapter 2 Supplemental Figures and Tables 
 
 
Supplemental Figure 2.1. Photomicrographs of OECs, CACs and Lymphocytes adhered to HMVECs. Low 
magnification images were used to quantify cell number adhered per area.  Scale bars are 200µm. 
 
 
 
Supplemental Figure 2.2. Relative integrin expression of OECs and CACs. An antibody adhesion-based array was 
used to assess integrin expression. Data are scaled to negative controls and presented as Mean ± SEM from three 
separate experiments. 
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Supplemental Figure 2.3. OEC adhesion to HMVECs with recombinant human soluble ICAM protein added. 
Soluble ICAM reduces adhesion to an equivalent level as the addition of a β2 antibody. Mean ± SEM. 
 
 
Supplemental Figure 2.4. ICAM surface coating method verification. ICAM was coated on the surface in Carbonate 
Buffer (pH=9.5) or PBS (pH=7.4) overnight at 4
o
C. A primary ICAM antibody (or IgG control) was used to detect 
ICAM on the surface, with an Alexa-fluor 488 secondary antibody used to generate signal. Mean ± SD. 
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Supplemental Figure 2.5. Parallel flow channel design and characterization. A) Photo of PDMS flow channel 
mounted on a glass slide. B) Table of experimental parameters. C-E) A COMSOL model was generated to verify 
channel design and flow properties, including streamlines (C), velocity profile in the XY plane (D), and parabolic 
velocity profile in ZY plane (flow is in X-direction, E). Units in D and E legends are m/sec. 
 
Experimental Parameters
Channel Height (h) 80µm
Flow Rate (Q) 10 µl/min
Average Flow Velocity ~200 µm/sec
Shear Stress
(T = 6µQ / h2w)
~0.1 dyn/cm2
inlet outlet
2 cm
1 cm
Y
Z
A
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D
E
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Supplemental Figure 2.6. Accumulation of fluorescent OECs in the lungs for different routes of systemic 
administration. A) IVIS image of lungs after cardiac injection (top), tail vein injection (middle), or no injection 
(bottom) of DiD-labeled OECs. B) Quantification of fluorescence shown in (A). 
 
 
Supplemental Figure 2.7. Detection of OECs by immunohistochemistry on mouse muscle sections. A-B) Muscle 
sections were stained for OECs after systemic delivery via a cardiac injection into mice which had undergone 
ischemia surgery (A, arrows indicate identified OECs), or after direct injection of OECs into the hind-limb muscle 
tissue (B). A primary Human CD31 antibody was used for OEC detection, with an Alexa-fluor 647 fluorescent 
secondary used for visualization. Negative controls were with secondary antibody only. Scale bars are 50µm. 
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Supplemental Table 2.1. 3-way ANOVA table for main effect analysis of Ischemia, Cell type, and VEGF+SDF 
treatment.
 
 
  
Tests of Between-Subjects Effects
Source
Type III Sum of 
Squares
Degrees of 
Freedom
Mean Square F Statistic
Significance
(P)
Corrected Model 3.159E-5a 3 1.053E-05 4.220 .012
Intercept .000 1 .000 61.527 .000
F
a
c
to
r
Ischemia 7.041E-06 1 7.041E-06 2.822 .102
Cell Type ǂ 1.432E-05 1 1.432E-05 5.737 .022
Treatment (VEGF+SDF or Control) ǂ 1.023E-05 1 1.023E-05 4.101 .050
Error 8.984E-05 36 2.495E-06
Total .000 40
Corrected Total .000 39
F statistic for df(numerator)=1 and df(denomemator) = 39; α = 0.05 4.091
a. R Squared = .260 (Adjusted R Squared = .199)
ǂ Statistically Significant for α = 0.05
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APPENDIX B: 
Chapter 3 Supplemental Figures 
 
 
 
Supplemental Figure 3.1. Effect of temporal presentation of SDF in combination with a decreasing VEGF profile. 
A) Schematic of VEGF and SDF concentrations applied to create stable, increasing or decreasing profiles. B-D) 
Quantification of the number of sprouts per bead formed by OECs (B), HUVECs (C), and HMVECs (D) at 72 
hours. Mean ± SD, n=4. * p < 0.05. 
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Supplemental Figure 3.2. Changes in secretion of factors from OECs and CACs with VEGF+SDF exposure. A) 
Chemiluminescent images of array membranes used for analysis of secreted factors from OECs and CACs with 
cytokine location map shown below. B) Relative change in secretion of factors when VEGF+SDF is applied to 
OECs or CACs, as measured by the angiogenesis array shown in A. C) Relative change in secretion of factors when 
VEGF+SDF is applied to OECs or CACs, as measured by ELISA. 
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APPENDIX C: 
Dual Compartment Microfluidic Device for Studying Endothelial Progenitor 
Adhesion and Migration 
 
Purpose of Studies 
The objective was to develop a microfluidic device that could be used to quantitatively study endothelial 
progenitor recruitment in a model system that mimicked relevant physiological characteristics
1
. 
Specifically, the device had two channels, representing a vascular compartment and an extracellular 
compartment; these were separated by a membrane on which endothelial cells were grown. The device 
was used to test the effect of SDF presentation from the extracellular compartment on the adhesion and 
migration of endothelial progenitors flowing through the vascular compartment. Because the flow in a 
microfluidic device is laminar, diffusion limits molecular transport from one compartment to the other, in 
addition to the barrier function imposed by the porous membrane and endothelial monolayer
2
. A 
diffusion-based flow regime was quantitatively modeled, and transport of SDF through the endothelial 
layer was then experimentally measured. This model could then be adapted to understand the 
concentrations and types of gradients that are necessary to induce endothelial progenitor adhesion to 
mature endothelial cells as well as migration through the monolayer. 
Experimental Setup 
Two channel microfluidic devices were fabricated as shown in Figure C1. Endothelial cells were grown 
on top of the porous membrane separating the two channels. SDF was then added to the media and flowed 
through the bottom channel and was re-collected after exiting the top and bottom channels so that the 
concentration could be measured. Outgrowth Endothelial Cells (OECs) were flowed through the top 
channel (vascular compartment) as SDF was presented from the bottom channel (extracellular 
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compartment) to test for increased adhesion to endothelial cells and to determine if SDF enhances 
migration through the monolayer. Last, a diffusion-based flow model of the microfluidic device was 
developed in COMSOL, and was used to predict the shape of the gradient formed by the experimentally-
measured SDF concentration. 
 
Figure C1. Fabrication of dual-compartment microfluidic device. A) Two PDMS channels separated by a 10µm 
thick spin-coated PDMS membrane with 10µm pores. Channels and membrane were permanently bonded together 
with following plasma treatment. B) Top view of device. C) View down the channels. Device design and fabrication 
was adapted from [1]. 
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Results 
Endothelial cells (HMVECs) were cultured on top of the membrane until confluent monolayers formed 
(Figure C2). Monolayer formation was verified prior to beginning SDF diffusion testing.  
 
Figure C2. Microfluidic device with endothelial cell monolayers. A) Schematic of endothelial cells growing on the 
membrane. B) Low resolution image of endothelial cells in the top channel only. C) Confluent layer of endothelial 
cells.  
 
COMSOL was used to create a quantitative model of the gradients of SDF produced by diffusion as it 
flows through the channel (Figure C3). No membrane was incorporated in this model. When SDF was 
allowed to diffuse across an endothelial monolayer, 9% of the total SDF delivered was transported into 
the vascular channel. The model predicted that diffusion would allow 27% of the total SDF delivered to 
cross into the opposite channel (Figure C3). The presence of the membrane and endothelial cells reduced 
the total SDF crossing the barrier by 1/3. The model was then used to predict the shape of the gradient 
when only 9% of the total SDF is transported to the opposite channel by diffusion alone (Figure C3).  
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Figure C3. Changes in the concentration gradient of SDF down the length of the 2cm channel. A) Theoretical model 
of SDF concentration in the channel as media flows at 25µl/hr. Model is based on diffusion only. B) Schematic of 
experimental set up for measuring SDF transport from the extracellular compartment (bottom) to the vascular 
compartment (top). Note channel height labels are altered to match the model. C) Amount of SDF diffused into the 
vascular compartment of the total delivered. Theoretical amount is calculated from the COMSOL model, and 
experimental was measured using an ELISA. D) Concentration gradients of SDF at the entrance and exit of the 
microfluidic device. The experimental concentration gradient is determined using the model based on 9% of the total 
SDF crossing into the vascular compartment. 
 
OECs were flowed through the vascular compartment as SDF was presented from the extracellular 
compartment. Videos were captured of this process to monitor OEC adhesion to the endothelial cells (data 
not shown). OECs adhered to endothelial cells were kept in culture for 24 hours following their 
administration (Figure C4). 
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Figure C4. OEC adhesion to endothelial cells in the microfluidic device. A) Schematic of adhesion assay setup. SDF 
was presented from the bottom channel to OECs flowing through the top channel. B) Fluorescently-labeled OECs 
that remained adhered to the endothelial cells 24 hours after delivery. C) Overlay of phase contrast image of 
endothelial cells on the membrane and a fluorescent image of adhered OECs. Channel width is 400µm. 
  
Summary of Outcomes and Possible Future Studies 
A two-compartment microfluidic device was capable of presenting SDF from the extracellular 
compartment to endothelial progenitors flowing through the vascular compartment. The device also 
permitted adhesion of OECs and the possibility to observe their migration through the endothelial 
monolayer. 
These studies were completed prior to collecting any of the data that is included in Chapters 2 or 3 of this 
thesis, and the mechanisms of adhesion by OECs and CACs were not yet understood. There are many 
possible future experiments that could be completed to develop a quantitative understanding of OEC and 
CAC responses to SDF exposure. First, a thorough characterization of the transport of SDF across the 
endothelial monolayer should be completed with multiple concentrations of SDF used. A permeability 
coefficient for this process could additionally be calculated
3
. This would allow the development of a more 
relevant model of the gradients of SDF that are formed in the device, and how the gradient likely changes 
between the entrance and exit of the device. With this understanding, adhesion assays could then be 
completed with this device. For example, if the density of adhesion events changes down the length of the 
Endothelial Cells (HMVECs)
+ SDF
Endothelial Progenitor Cells (OECs)
A B C
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channel, this could indicate a preferential adhesion when exposed to the specific SDF gradient presented 
in that region. Migration events could also be spatially monitored, and locations of enhanced migration 
could be used as an indicator of gradients that may be effective for inducing recruitment. If cells 
demonstrate selectivity for specific gradients, this information could be translated to the development of a 
therapy for enhancing endothelial progenitor recruitment. 
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APPENDIX D: 
Systems to Study Cell Migration in Response to Chemotactic Gradients 
 
Purpose of Studies 
Endothelial progenitor migration is one of the key steps in the cell recruitment process. A better 
understanding of the types and magnitude of gradients of chemotactic factors that enhance cell migration 
could translate to improved recruitment-inducing biomaterials. Here two in vitro systems were employed 
to study endothelial progenitor migration in response to well-controlled gradients of SDF and in a 3D 
model replicating the extracellular matrix environment. 
Experimental Setup 
A PDMS-based, gradient-generating microfluidic device was used to monitor OEC migration in two 
dimensions.  A gradient of SDF was introduced and OEC migration was monitored over time using time-
lapse microscopy. Second, OECs and CACs were seeded into a 3D collagen matrix in the corner position 
of an L-shaped, PDMS mold. Collagen containing SDF or VEGF was placed in one arm of the mold, and 
collagen without growth factor was placed in the other arm as a control. Migration of cells through the 
matrix was monitored over time using time-lapse microscopy. 
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Results 
OEC were seeded into 2D gradient-generating microfluidic device and migration was tracked over time 
(Figure D1). Fluorescently labeled cells could be tracked to determine migration direction and velocity 
(data not shown). The theoretical concentration gradient in this device follows the non-linear equation 
C = C0*x
4.2
 
where C0 is the initial chemokine concentration and x is the position across the channel
1
. 
 
Figure D1. Experimental setup and OEC monitoring in 2D migration microfluidic devices. A) Image of microfluidic 
device (left), with non-linear gradient-generating design highlighted (top right), and fluorescently-labeled OECs 
seeded in the device. B) Example images of two positions used for cell tracking in a time-lapse experiment at the 
start (t=0) and end (t=4hr) of the experiment. The channel is 300µm wide. Device design was adapted from [1]. 
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OECs and CACs were additionally seeded in a collagen matrix into L-shaped PDMS mold to monitor 
migration in 3D over 4 hours (Figure D2).  
 
Figure D2. Three-dimentional device used to track endothelial progenitor migration in response to chemokines. A) 
Image of mold used to fabricate PDMS device, with cell and chemokine placement indicated. Each square chamber 
is 3mm x 3mm. B) Example tracking of OECs toward a VEGF concentration source over 4 hours. End positions are 
indicated by spots. Device design was adapted from [3,4]. 
 
Summary of Outcomes and Possible Future Studies 
Feasibility of tracking OEC migration in 2D and both OEC and CAC migration in a 3D collagen matrix 
toward a chemokine source was demonstrated in these studies. A full quantitation of migration kinetics 
for OECs and CACs towards VEGF and SDF has not yet been completed in these devices. Both systems 
permit measurement of cell migration and calculation of representative population migration variables 
(e.g. directional preference or speed and velocity)
1–4
. The more physiologically relevant 3D system could 
further be adapted for testing the effects of chemokines released from a biomaterial on migration by 
placing the material in the source chamber
4
. 
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These types of devices could be used to gain a quantitative understanding of the types of gradients (e.g. 
linear or non-linear) and the magnitude of the concentration gradients for different chemotactic factors 
that effectively enhance cell migration
5
. This information could then be translated into improved 
biomaterial designs for increasing endothelial progenitor recruitment. 
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APPENDIX E: 
Recruitment of Bone Marrow Cells to SDF-releasing PLG Scaffolds 
 
Purpose of Studies 
Endothelial progenitor cells originate in the bone marrow and their mobilization into the circulation from 
the bone marrow is controlled by gradients of SDF
1–5
. The hypothesis of this experiment is that local 
release of SDF from a PLG scaffold creates a gradient capable of recruiting circulating bone marrow 
cells. 
Experimental Setup  
PLG scaffolds loaded with SDF or control scaffolds were created by the gas foaming method, followed 
by leaching to dissolve incorporated salt crystals and induce pore formation. These scaffolds were 
implanted into the hind-limbs of mice. Bone marrow cells were then isolated from GFP mice and 
introduced into the circulation of the mice with the scaffold implants by intraocular injection. Six days 
after GFP-bone marrow injection, scaffolds were collected and analyzed for the presence of GFP+ cells 
by flow cytometry. (See Figure E1 for experimental timeline.) 
 
Figure E1. Experimental timeline for GFP bone marrow cell recruitment to PLG scaffolds. Scaffolds were implanted 
on Day 0, followed by GFP bone marrow cell isolation and delivery to mice with scaffolds on day 1. Scaffolds were 
then collected and analyzed on day 7.  
 
 
Day 0 Day 1 Day 7
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Results 
PLG scaffolds were created that steadily released SDF over time (Figure E2). A large portion of bone 
marrow cells were found to express CXCR4, the receptor for SDF (Figure E3). Scaffolds containing SDF 
recruited more GFP+ cells than blank scaffolds (Figure E3). 
 
Figure E2. Cumulative release of SDF from porous PLG scaffolds. n=3. 
 
A 
 
B 
 
Figure E3. Bone marrow cell expression of CXCR4 and recruitment to SDF scaffolds. A) CXCR4 Expression. B) 
Number of GFP cells collected from PLG scaffolds on day 7. n=4. 
 
Summary of Outcomes 
SDF-loaded PLG scaffolds demonstrated the ability to enhance the recruitment of bone marrow cells, 
which express CXCR4. This result implies that scaffolds releasing SDF may also be able to recruit 
endothelial progenitor cells, since they also express CXCR4. 
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APPENDIX F: 
Expanded Flow Cytometry Characterization of Circulating Angiogenic Cells 
 
Purpose of Studies 
The objective of this experiment was to further characterize CACs with surface markers used to identify 
sub-populations of monocytes. These monocyte sub-populations include Classical/Inflammatory 
CD14
++
/CD16
-
 monocytes, Non-Classical/Resident/Patrolling CD14
+
/CD16
++
 monocytes, and 
Intermediate CD14
++
/CD16
+
 monocytes
1–4
. Integrin expression was also characterized. 
Experimental Setup  
CACs were isolated as usual and then were stained for the expression of CD45, CD14, CD16, β2, αL, and 
αM. 
Results 
CACs stained positive for CD45, CD14, β2, αL, and αM. Approximately 20% of the CACs were positive 
for CD16. β2, αL, and αM staining confirms the expected high levels of expression for these integrins. 
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Figure F1. Flow cytometry characterization of CACs. A) Expression of hematopoietic marker CD45, monocyte 
marker CD14, and CD16. The combination of CD14 and CD16 is used to identify sub-populations of monocytes. B) 
Histograms of β2, αL, and αM integrin expression. 
 
Summary of Outcomes  
CACs that were co-stained with CD14 and CD16 show that all CD16+ cells also express a high level of 
CD14. In relation to the better understood sub-populations of monocytes, approximately 80% of CACs 
exhibit the Classical/ Inflammatory (CD14
++
/CD16
-
) phenotype, while 20% show a similar phenotype to 
the Intermediate monocyte population (CD14
++
/CD16
+
). These results are suggestive of a heterogenous 
population of CACs, which may have implications for their behavior and recruitment capabilities in vivo. 
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APPENDIX G: 
Comparison of OEC vs. HUVEC network formation in fibrin-PLGA scaffolds 
 
Purpose of Studies 
When OECs and HUVECs or HMVECs were placed in direct competition in sprouting assays, OECs 
demonstrated a higher potential to initiate sprouts. OECs and mature endothelial cells are both capable of 
forming networks of blood vessels in three-dimensional matrices, which anastomose with host vessels 
upon implantation
1–3
. Combination fibrin-PLGA scaffolds were used here as another method to compare 
the neovascularization potential of OECs and HUVECs. 
Experimental Setup  
OECs or HUVECs were seeded with fibroblasts into fibrin-PLGA scaffolds, and were placed in culture in 
EGM-2 media (Lonza #CC-3162) for 5 and 8 days. At these time points, scaffolds were fixed and stained 
for CD31, and then were imaged with a confocal microscope. 
Results 
Both OECs and HUVECs condensed into vessel-like networks. Qualitative differences in network 
formation were not overly dramatic on day 5 or 8 (Figure G1), but OECs appear to form a more 
connected network on day 5, and may possibly form a more branched network on day 8. More rigorous 
quantitative analysis is necessary to make strong conclusions about these differences though. (Methods 
for quantitative image analysis were still in development at the time these studies were completed.) 
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Figure G1. Fluorescent images of vessel-like network formation by OECs and HUVECs on days 5 and 8. 
 
Summary of Outcomes 
The network forming potential of OECs and HUVECs were compared in these studies. Images suggest 
OECs may condense to form networks in an accelerated manner compared to HUVECs, but this was not 
strongly apparent by qualitative analysis alone. Further studies and quantitative analysis using this system 
may confirm that OECs exhibit enhanced network forming capabilities, similar to the enhanced sprouting 
potential demonstrated in three-dimensional angiogenesis assays.   
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APPENDIX H: 
Auto-fluorescence Characterization of Ischemic Hind-limbs Imaged with the  
In Vivo Imaging System (IVIS) 
 
Purpose of Studies 
Use of the IVIS machine is a fast and quantitative way to measure localization of particles or cells. In my 
studies, the IVIS machine was used to characterize endothelial progenitor cell recruitment to ischemic 
hind-limbs, until control experiments revealed that the ischemic limbs are highly auto-fluorescent. The 
IVIS machine was not sensitive enough to discriminate ischemia due to auto-fluorescence from cell 
accumulation. The data presented here characterizes the auto-fluorescence across the entire range of 
excitation and emission wavelengths available on the IVIS. 
Experimental Setup 
Bare ischemic and non-ischemic hind-limbs were imaged using the IVIS at various time points following 
surgery. Auto-fluorescence of the hind-limb tissue region was then quantified. 
Results 
Ischemia leads to significantly high levels of auto-fluorescence in bare hind-limbs across many 
wavelengths. No differences are detected when the skin remains on the mouse (data not shown). Longer 
wavelengths of light tend to show less background fluorescence in the non-ischemic limbs, and also a 
lower ratio of the fluorescence in the ischemic limb to the non-ischemic limb (Figure H1).  
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Figure H1. Auto-fluorescence characterization in ischemic hind-limbs on day 3 following surgery. A-B) Example 
images of auto-fluorescence in the ischemic hind-limb (left side) compared to the non-ischemic limbs (right side), 
shown both without (A) and with (B) ROI’s used for quantification. C-D) Auto-fluorescence measurements, in units 
of Radiant Efficiency, in the ischemic limb (C) and non-ischemic limb (D). E) Ratio of radiant efficiency 
measurements (ischemic / non-ischemic). 
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Auto-fluorescence of the ischemic limb persisted for nearly two weeks after surgery at the excitation 
wavelength of 640nm and the emission wavelength of 680nm (Figure H2). 
 
Figure H2. Persistence of increased auto-fluorescence following ischemia surgery at excitation and emission 
wavelengths of 640nm and 680nm, respectively. A) Representative images of hind-limbs exhibiting increased auto-
fluorescence at multiple time points following surgery. b) Quantification of the auto-fluorescence over time, shown 
as the ratio of the radiant efficiency in the ischemic to the non-ischemic limb.  
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A better method for detecting cell localization is to use luciferase-expressing cells. Ischemia surgery did 
not cause auto-luminescence in the ischemic limb. 
 
Figure H3. Luminescent images taken with the IVIS 3 days following surgery. A) Luminescence without injection 
of luciferase-expressing OEC (negative control) on day 3 after ischemia surgery. B) Luminescent image of hind-
limbs from a mouse which underwent ischemia surgery and received an intra-cardiac injection of luciferase-
expressing OECs. OECs localize to the ischemic hind-limb (left side) more than in the non-ischemic hind-limb 
(right side). 
 
Summary of Outcomes 
The data presented here is meant to be informative and useful for future users of the IVIS in conjunction 
with ischemia surgery. These data highly suggest that the best method to detect localization of cells 
within the ischemic hind-limb is by using luciferase-expressing cells, since auto-fluorescence is present 
across nearly all available wavelengths, and persists for up to two weeks. The IVIS may still be useful for 
detection of very bright particles, especially because particles are often detectable without the removal of 
the skin.   
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APPENDIX I: 
Protocol for Adhesion of OECs/CACs to Endothelial Cells 
Materials 
Human Collagen IV – BD #354245 
12mm diameter glass slides – VWR #100500-834 
TNFα – Peprotech #300-01A 
Octadecyle Rhodamine – Life Technologies #O-246 
Endothelial Growth Media (EGM-2MV – Lonza #CC3202 or EGM-2 – Lonza #CC3162) 
ProLong Gold Anti-fade Reagent with Dapi – Life Technologies #P36935 
 
Procedure 
 
Preparation 
1) Place individual glass slides in wells of 24 well plate (n=6 per condition) 
2) Place well plate containing slides in Plasma Generator with lid open; Turn on plasma for 1 min 
3) Remove plate and immediately transfer to biosafety cabinet and coat with COL IV for 1 hr at 
room temp or overnight at 4
o
C 
a. Dilute COL IV to5µg/ml in 10mM acetic acid 
4) Rinse slides 2X with excess PBS 
5) Place 0.5ml endothelial growth media (EGM-2MV for HMVECs or EGM-2 for HUVECs) into 
each well 
6) Seed HMVECs or HUVECs by gently dropping 100μl of cell suspension onto center of glass 
slide  
7) Change media every other day until HMVECs have formed a  95% confluent monolayer of cells 
on the glass slides prior to starting experiment 
8) Apply activation molecule (TNFα) to wells ~8 hrs prior to start of experiment (overnight) 
9) Apply Octadecyl Rhodamine to OECs/CACs in culture overnight  
Perform Experiment   
1) Change media in wells to EBM-2 + 5% FBS (0.5ml/well); for some wells, add 500ng/ml SDF for 
1 hour prior to applying cells for surface presentation 
2) Trypsinize and prepare a single cell suspension of OECs/CACs (50,000 cells/well in 100μl) 
3) Change wells with SDF to EBM-2 + 5% FBS; for SDF presentation during adhesion, change 
media to 125ng/ml SDF (0.4ml/well) immediately before applying cells (gets diluted to final 
concentration of 100ng/ml with cell addition) 
4) Gently drop 100μl of cell suspension onto center of glass slide; place in incubator for 1 hour 
5) To stop experiment, lift slide from well and dip in PBS while holding with tweezers, move 
around slightly 
6) Place slide in 20% Methanol in PBS for 5 min 
7) Mount on glass slide with Dapi-Prolong Gold  
8) Leave at room temp over night, cover with foil to protect from light 
9) Place in fridge in slide box the next day until ready to image 
10) Take 6 images per glass slide at 5X magnification; count fluorescent cells adhered for 
quantification 
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APPENDIX J: 
Protocol for ICAM Adhesion Assay 
Materials & Buffers 
Recombinant Human Soluble ICAM (rhsICAM) – eBioscience #BMS313 
β2 Antibody – CalBiochem #217660 
Recombinant Human SDF – R&D #350-NS 
TrypLE Select (without phenol red) – Life Technologies #12563029 
CyquantGR dye – Life Technologies #C7026 
 
Adhesion Buffer 
 0.1%w/v BSA, 25mM HEPES in HBSS 
 
Lysis Buffer 
3mM Na2HPO4, 0.8mM NaH2PO4, 0.1M NaCl, 0.25%v/v Triton-100 in ddH2O 
 
Procedure 
 
Plate preparation 
1) Place a non-TC 48 well plate in Plasma Generator. Turn on plasma for 1 min. 
2) Immediately coat the plate with 5μg/ml rhsICAM, 80μl/well in a biosafety cabinet. 
3) For negative control apply 80μl of 1% BSA in PBS to each well. 
4) Parafilm wrap plate and place at 4oC overnight 
Perform Experiment 
5) Aspirate ICAM and apply 200μl of 1%BSA in PBS for 1 hr at room temp 
6) Rinse OECs/CACs in PBS, then remove using 5mM EDTA in PBS for ~15 min (must tap hard or 
pipette up and down to remove cells) 
7) Centrifuge for 5 min at 1200 rpm. 
8) Resuspend in Adhesion Buffer; Count. 
a. Want a minimum of 100K cells/well; 100μl/well 
9) Divide cells into tubes for β2 block or SDF stimulation 
a. β2 block : 0.5μg/sample for 5-10 min prior to applying cells to well 
b. SDF : 300ng/ml immediately prior to applying cells to well (dilute by 3X when added to 
well for 100ng/ml final concentration) 
10) Apply cells to wells 
a. Aspirate BSA block 
b. Apply 200μl Adhesion Buffer to each well 
c. Dilute cells so that 100μl of cells are applied to each well 
d. Add cells to one or two wells (never rinse) – positive controls (100%) 
11) Place plate in incubator for 30 min 
146 
 
a. After 30 min observe plate under microscope – visually check for adhered vs. unadhered 
cells 
12) ***Thaw Cyquant GR dye*** 
13) Swirl plate and tilt to remove un-adhered cells 
14) Rinse with 0.5ml PBS in each well (pipette to top side of well with plate tilted and let run down); 
do this 3X; BE GENTLE 
15) Add 300μl of TrypLE Select and let incubate at 37oC for 5 min 
16) Observe cell detachment under the microscope 
17) Pipette cells up and down to help with removal 
18) Add 100μl of Lysis Buffer with Cyquant Dye to each well 
a. 100μl Lysis Buffer/well 
b. Add 4μl of CyquantGR Dye per 300μl of lysis buffer 
19) Let sit at room temp for 15 min, cover plate with foil 
20) Check fluorescence under microscope – green filter; check for lysis 
21) Pipette up and down in each well to mix 
22) Take 2x 150μl from each well and place into 2 wells of a 96-well black bottom plate 
23) Read fluorescence on plate reader at ex:485nm, em: 528nm 
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APPENDIX K: 
Protocol for Adhesion Assay in PDMS-based Wide Flow Channel 
Materials 
PDMS (Sylgard ® 184 Silicone Elastomer Kit) 
Human Collagen IV – BD #354245 
Recombinant Human SDF – R&D #350-NS 
TrypLE Select (without phenol red) – Life Technologies #12563029 
Endothelial Growth Media (EGM-2MV – Lonza #CC3202 or EGM-2 – Lonza #CC3162) 
EBM-2 – Lonza # CC3156 
ProLong Gold Anti-fade Reagent with Dapi – Life Technologies #P36935 
 
Other materials for fabricating devices (tubing, “Y” branch connectors, blunt end needles, metal 
connectors) are common microfluidics laboratory supplies. 
 
Procedure 
Device Preparation  
1. Prepare tubing and UV sterilize (Figure K1). 
2. Cut out PDMS wide channel from mold. Cut to fit on a microscope slide. Punch 1.5mm holes at 
channel ends. Remove dust with tape.  
3. Place PDMS channel and clean microscope slide into plasma generator. Turn on for ~1  min. 
Once vacuum has re-pressurized, remove PDMS and slide and bond together. Be careful not to 
touch middle of channel so as not to bond this region. Place components in a petri dish. (Figure 
K2) 
4. Quickly move to a biosafety cabinet and pipette ~100μl of COL IV (5µg/ml diluted in 10mM 
acetic acid) into the channel, filling the device. 
5. Store for 3 hours at room temperature or wrap petri dish with parafilm and store overnight at 4oC. 
6. Place a few ml of media in a petri dish and put in incubator (37oC, 5% CO2) for 30 min. 
7. Fill sterile tubing with warm, CO2-adjusted media, using a 1ml slip tip syringe. Make sure there 
are no bubbles. 
8. Place metal component into PDMS hole at end of device, being careful not to introduce bubbles. 
9. Place short tube in opposite end of device. Push excess media through channel, thoroughly 
rinsing COL IV solution. Clamp closed with binder clips and place in incubator (3-24 hours). 
Return excess media to incubator as well. 
Cell Culture in Device 
1. Use a nearly-confluent T75 of HMVECs to fill ~4 devices.  
2. Trypsinize as usual and resuspend in 1ml of media from petri dish in incubator.  
3. Place 22G needle on 1ml slip tip syringe and draw up cell solution into syringe, maintaining a 
small air bubble next to the plunger and being careful to keep syringe pointed down. Make sure 
there are no bubbles in the solution (besides the one at the plunger). 
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4. Verify there are no bubbles in the device or tubing. Adjust binder clips for cell seeding. 
5. Push a small amount of cell solution to end of needle. Insert needle into the short tube at the 
channel exit, and pinch around the needle. Introduce approximately 150-200μl of cell solution 
through the device, or until the solution exiting the “Y” branch is slightly cloudy. 
6. Pinch off tube with binder clips, verify seeding using the microscope, and place device in 
incubator for 3-6 hours to allow cells to attach. 
7. Place 10ml of media per device into a T25, and place upright in incubator to allow temperature 
and CO2 to equilibrate. 
8. Hook up inlet tubing to a 10 ml syringe with plunger removed and place upright in a tube rack. 
Fill syringe with equilibrated media. Fill tubing with media, making sure there are no bubbles. 
9. Remove short tube at the outlet and insert long tube attached to a 10 or 20ml syringe.  
10. Place device in incubator and hook up the syringe at the outlet to the syringe pump. Flow media 
at 10μl/min. Adjust binder clips for proper cell culture.  
11. Allow endothelial cells to grow until a confluent monolayer is formed. Make sure to replenish 
media. DO NOT LET DEVICE RUN DRY. 
Preparation of OECs/ CACs 
1. Use TrypLE Select to remove cells from surface, centrifuge and resuspend in 5-10ml PBS. 
Centrifuge and resuspend again. 
2. Stain OECs/CACs with 1μM CFSE according to manufacturer’s protocol. This takes 
approximately 45 min total. Plan accordingly to coordinate with device preparation so cells do 
not sit in suspension for long prior to starting experiment.  
3. Perform the final resuspension in EBM-2 + 5% FBS to a concentration of 5M cells/ml. Divide 
into tubes as necessary for ±SDF exposure during adhesion. 
Adhesion Assay 
1. Prepare EBM-2 + 5% FBS and place in T25 in incubator to allow temperature and CO2 to 
equilibrate. Use this for all remaining steps. Return flask to incubator when not in use. 
2. Change media source-syringes to the 3 ml size. Fill with ~1ml EBM-2 + 5% FBS. Let media run 
over cells in device to rinse away normal growth media. Clamp off tubing and place devices in 
incubator for ~1 hour. 
3. For the SDF-surface presentation condition, remove excess rinse media from 3 ml syringe and 
add ~300μl of EBM-2 + 5% FBS supplemented with 500ng/ml SDF. Let this media run over the 
cells, clamp with binder clips, and place in incubator for 1 hour.  
4. Rinse SDF-surface presentation device with fresh EBM-2 + 5% FBS. 
5. Remove excess media from source syringe. 
6. Draw up OEC/CAC cell suspension into 1ml slip tip syringe with a 22G needle attached using the 
same methods as for endothelial cell seeding. For SDF-during adhesion conditions, add 100ng/ml 
SDF to the cell suspension before drawing into syringe. 
7. With path into the device clamped off, insert the needle into the short end of the tube off of the 
“Y” branch. Fill upstream tubing with 200μl of cell solution (1M cells). Some solution will likely 
back-fill the syringe. Clamp off the short tube after filling with cells. 
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8. Hook up device outlet syringes to the syringe pump. Adjust binder clips so that cell may flow 
through the device. Start flow over the device (10μl/min). 
9. After ~18 min, add 200μl of EBM-2 + 5% FBS to the source syringe. Repeat after another ~18 
min. 
10. Clamp off device, remove from incubator and verify under the microscope that OECs/CACs in 
the device are adhered and not still floating/flowing through the device. 
11. Carefully remove tubing from device and very slowly pipette a dilute solution of PBS containing 
dapi through the channel. Cover top of device with a cover slip. 
12. Image device immediately. Take pictures in as many locations as possible (where the endothelial 
monolayer confluence is verified). 
 
 
 
Figure K1. Tubing components necessary for cell culture in the flow device. 
A) Inlet tubing. B) Outlet tubing. C) Cell-seeding short tubing. 
 
 
 
Figure K2. PDMS channel bonded to a glass slide. 
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APPENDIX L: 
Protocol for Muscle Cell Isolation and Staining for Flow Cytometry 
Materials & Buffers 
Collagenase II – Life Technologies #17101-015 
Dispase II – Roche #04942078001 
Normal Goat Serum – VWR # 100180-976 
CD11b Antibody – eBioscience #25-0112  
F4/80 Antibody – eBiosceince #12-4801 
Gr1 Antibody – eBioscience #11-5931 
 
FACS Buffer  
0.1% BSA in PBS (or BD #554657) 
 
Procedure 
Muscle cell collection and digestion 
1) Prepare Collagenase II solution (250U/ml) in DMEM  
a. Will need 4ml/sample total 
2) Pipette 2 ml of Collagenase solution into a 15ml tube for each muscle sample 
3) Record weight of each tube 
4) Collect muscles of interest from mouse legs 
a. Using scissors, cut up each muscle into as small of pieces as possible  
b. Wipe down scissors with isopropanol of ethanol between chopping each muscle (to 
prevent mixing of cells) 
5) Place muscle chunks into 2ml of Collagenase solution; make sure all pieces are in solution (i.e. 
none stuck to the sides of the tube) 
6) Weigh tubes again to determine mass of muscle collected 
7) Place tubes on shaker at 37oC for 1.5hr 
8) Using a short glass Pasteur pipet, pipet up and down gently until muscle solution is smooth (no 
brown chunks); do this in 15ml tube and change Pasteur pipette between every sample 
9) Add 3-5 ml PBS to each tube  
10) Centrifuge at 500g for 5 min (re-spin if muscle has not pelleted well) 
11) Remove supernatant 
12) Resuspend in Collagenase II / Dispase / media solution 
a. Prepare 6U/ml dispase in DMEM (1ml/sample) 
b. Add 1 ml of 6U/ml dispase (resuspend using 1 ml pipettor) 
c. Add 2 ml of 250U/ml Collagenase II (prepared earlier) 
d. Add 3 ml media DMEM 
13) Place tubes on shaker at 37oC for 1hr 
14) Vortex each tube for 1 minute on max speed to release the cells 
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15) Pass cell suspensions through 40μm filters into 50 ml tubes using 10ml pipettes to push solution 
through the filter 
16) Add 5ml PBS to each 50ml tube through the filter to rinse cell suspension through 
17) Centrifuge at 500g for 5 min; Remove supernatant 
18) Resuspend each tube into 200μl RBC lysis buffer 
a. Let sit for 5 min at RT; swirl a few times to mix cell suspension 
19) Add 800μl PBS 
20) Transfer cell suspension into 2ml brown tubes 
a. Optional: add a small volume of pfa to fix the cells (~100ul of 4% pfa is sufficient) 
b. Place tubes in fridge if not going to run flow/stain cells immediately  
 
 
Figure L1. Example images of cell suspension after completing the muscle digestion procedure. 
A) Phase contrast image. B) Bright field image. 
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Flow Cytometry Staining  
1) Centrifuge cells at 600g for 5 min  
2) After centrifuging in brown tubes, dump out supernatant 
3) Resuspend in FACS Buffer 
a. 600μl for ischemic limb 
b. 400μl for non-ischemic limb 
4) Pipette ~80-100μl per sample into wells of round bottom plate compatible with HTS system on 
flow cytometer 
5) Add 20μl blocking buffer to each tube/well; let sit 15 min at RT 
a. Blocking buffer: 10%NGS + 1% BSA in PBS 
6) Add primary antibody to each tube/well (5μl/sample; 0.25μg/sample); place tubes on ice for 45 
min, protect from light (Check antibody concentration to calculate volume of each antibody 
needed) 
7) Add 0.75ml FACS Buffer to each tube; centrifuge at 600g for 5 min, 4oC; Repeat twice 
a. Add 100ul if using round bottom plates, then centrifuge as above 
b. After centrifuging, dump supernatant into the sink by turning plate over quickly 
c. Resuspend each well in 200ul (use multi-channel pipettor; no mixing necessary until final 
resuspension)  
8) For 1o AB with fluorophore, after final spin, resuspend into 250μl FACS Buffer per well and 
place on ice protected from light until time to run samples 
9) Add 1μl hoescht or DAPI to each tube immediately before running samples 
 
 
 
